Психические расстройства у пациентов с сердечно-сосудистыми заболеваниями. Консенсус рабочих групп Российского кардиологического общества и Российского общества психиатров

Эксперты рабочих групп Российского кардиологического общества и Российского общества психиатров, Байкальской и Сибирской психосоматических ассоциаций разработали рекомендации по диагностике и лечению распространенных психических расстройств у пациентов с сердечно-сосудистыми заболеваниями. Положения документа основаны на результатах наиболее надежных научных исследований и рекомендациях авторитетных медицинских обществ, призваны информировать врачей о надлежащей клинической практике. Настоящий документ отражает позицию профессиональных организаций по актуальной междисциплинарной проблеме. 
Согласованный документ ориентирован на кардиологов, врачей общей практики, психиатров и врачей других специальностей, оказывающих помощь пациентам с сердечно-сосудистыми заболеваниями и коморбидными психическими расстройствами.

1. World Health Organization. Mental мHealth Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders. - Geneva: World Health Organization; 2023. - 152p. ISBN 978 92-4-008427-8

2. Байкальская психосоматическая ассоциация. Клинические рекомендации по психосоматической медицине. – Иркутск; 2024. - 36с. Доступно на: https://therapy.irkutsk.ru/ispm/psomatic6.pdf

3. Белялов Ф.И., Сумин А.Н., Гарганеева Н.П., Ларева Н.В., Петрова М.М., Петрунь ко О.В. и др. Психические расстройства и сердечно-сосудистые болезни: клинические рекомендации Байкальской психосоматической ассоциации и Сибирской психосоматической ассоциации. Комплексные проблемы сердечно-сосудистых заболеваний. 2024;13(3S):222-53. DOI: 10.17802/2306-1278-2024-13 3S-222-253

4. Бойцов С.А., Погосова Н.В., Аншелес А.А., Бадтиева В.А., Балахонова Т.В., Барбараш О.Л. и др. Кардиоваскулярная профилактика 2022. Российские национальные рекомендации. Российский кардиологический журнал. 2023;28(5):119-249. DOI: 10.15829/1560-4071-2023-5452

5. Министерство здравоохранения Российской Федерации. Российское общество психиатров. Депрессивный эпизод, рекуррентное депрессивное расстройство. 2024. 125с. Доступно на: https://cr.minzdrav.gov.ru/view-cr/301_3

6. Министерство здравоохранения Российской Федерации. Российское общество психиатров. Генерализованное тревожное расстройство. 2024. 121с. Доступно на: https://cr.minzdrav.gov.ru/view-cr/457_3

7. Министерство здравоохранения Российской Федерации. Российское общество психиатров. Паническое расстройство. 2024. 140с. Доступно на: https://cr.minzdrav.gov.ru/view-cr/456_3

8. Министерство здравоохранения Российской Федерации. Российское общество психиатров. Посттравматическое стрессовое расстройство. 2023. 200c. Доступно на: https://cr.minzdrav.gov.ru/preview-cr/753_1

9. Министерство здравоохранения Российской Федерации. Российское общество психиатров, Российская ассоциация геронтологов и гериатров. Когнитивные расстройства у лиц пожилого и старческого возраста. 2020. 239с. https://rgnkc.ru/fp-starshee-pokolenie/geriatricheskaya-pomosch/normativno-pravovaya-baza/5/2.pdf

10. Albus C, Waller C, Fritzsche K, Gunold H, Haass M, Hamann B et al. Significance of psycho-social factors in cardiology: update 2018: Position paper of the German Cardiac Society. Clinical Research in Cardiology. 2019;108(11):1175–96. DOI: 10.1007/s00392-019-01488-w

11. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder. Third Edition. 2010. 152p. Av. at: https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf

12. Colquhoun DM, Bunker SJ, Clarke DM, Glozier N, Hare DL, Hickie IB et al. Screening, referral and treatment for depression in patients with coronary heart disease. Medical Journal of Australia. 2013;198(9):483–4. DOI: 10.5694/mja13.10153

13. Frost JL, Rich RL, Robbins CW, Stevermer JJ, Chow RT, Leon KK et al. Depression Following Acute Coronary Syndrome Events: Screening and Treatment Guidelines from the AAFP. Av. at: https://www.aafp.org/pubs/afp/issues/2019/0615/od2.pdf. American Family Physician. 2019;99(12). PMID: 31194478

14. Ladwig KH, Baghai TC, Doyle F, Hamer M, Herrmann-Lingen C, Kunschitz E et al. Mental healthrelated risk factors and interventions in patients with heart failure: a position paper endorsed by the European Association of Preventive Cardiology (EAPC). European Journal of Preventive Cardiology. 2022;29(7):1124–41. DOI: 10.1093/eurjpc/zwac006

15. Lichtman JH, Froelicher ES, Blumenthal JA, Carney RM, Doering LV, Frasure-Smith N et al. Depression as a Risk Factor for Poor Prognosis Among Patients With Acute Coronary Syndrome: Systematic Review and Recommendations: A Scientific Statement From the American Heart Association. Circulation. 2014;129(12):1350–69. DOI: 10.1161/CIR.0000000000000019

16. Lichtman JH, Bigger JT, Blumenthal JA, Frasure-Smith N, Kaufmann PG, Lesperance F et al. Depression and Coronary Heart Disease: Recommendations for Screening, Referral, and Treatment: A Science Advisory From the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: Endorsed by the American Psychiatric Association. Circulation. 2008;118(17):1768–75. DOI: 10.1161/CIRCULATIONAHA.108.190769

17. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 2021;42(34):3227–337. DOI: 10.1093/eurheartj/ehab484

18. Vaccarino V, Badimon L, Bremner JD, Cenko E, Cubedo J, Dorobantu M et al. Depression and coronary heart disease: 2018 position paper of the ESC working group on coronary pathophysiology and microcirculation. European Heart Journal. 2020;41(17):1687–96. DOI: 10.1093/eurheartj/ehy913

19. Александровский Ю.А., Незнанов Н.Г. Психиатрия. Национальное руководство. – М.: ГЭОТАР-Медиа; 2022. - 1008с. ISBN 978-5-9704-7334-4

20. Roberts LW. The American Psychiatric Association Publishing textbook of psychiatry. - Washington, D.C: American Psychiatric Association Publishing; 2019. - 1362 p. ISBN 978-1-61537-256-0

21. Boland RJ, Verduin ML, Ruiz P, Shah A, Sadock BJ. Kaplan & Sadock’s synopsis of psychiatry. - Philadelphia: Wolters Kluwer; 2022. - 1173p. ISBN 978-1-975145-56-9

22. Levenson JL. The American Psychiatric Association Publishing textbook of psychosomatic medicine and consultationliaison psychiatry. - Washington, D.C: American Psychiatric Association Publishing; 2019. - 1561p. ISBN 978-1-61537-136-5

23. Лебедева Е.В., Нонка Т.Г., Репин А.Н., Шишнева Е.В., Счастный Е.Д., Симуткин Г.Г. и др. Современная психокардиология. – Томск: ООО Интегральный переплет; 2019. - 160с. ISBN 978-5-604-14671-2

24. Волель Б.А., Петелин Д.С., Романов Д.В., Воронова Е.И., Копылов Ф.Ю., Бекетов В.Д. Алгоритмы диагностики и терапии психических расстройств в общемедицинской практике. Учебное пособие. - М.: Издательство МАИ, 2020. - 78с. ISBN 978-5-4316-0765-3

25. Смулевич А.Б. Психосоматические расстройства. Руководство для практических врачей. 2-е изд. - М: МЕДпресс-информ; 2019. - 496с. ISBN 978-5-00030-778-6

26. Белялов Ф.И. Психосоматика. 10-е изд. - М.: ГЭОТАР-Медиа; 2025. - 452c. ISBN 978-5-9704-9004-4

27. Медведев В.Э. Депресcивные расстройства. В кн.: Путеводитель врачебных назначений. Современное руководство для практикующих врачей. Том 6. C.57-69. – М.: Бионика Медиа; 2018. ISBN 978-5-906444-09-7

28. МКБ-11. Глава 06. Психические и поведенческие расстройства и нарушения нейропсихического развития. Статистическая классификация. – М.: КДУ, Университетская книга; 2021. - 432с. DOI: 10.31453/kdu.ru.91304.0143. ISBN 978-5-91304-954-4

29. World Health Organization. Clinical Descriptions and Diagnostic Requirements for ICD-11 Mental, Behavioural and Neurodevelopmental Disorders. - Geneva: WHO; 2024. - 852p. ISBN 978-92-4-007726-3

30. Stein DJ, Szatmari P, Gaebel W, Berk M, Vieta E, Maj M et al. Mental, behavioral and neuro-developmental disorders in the ICD-11: an international perspective on key changes and controversies. BMC Medicine. 2020;18(1):21. DOI: 10.1186/s12916-020-1495-2

31. Levis B, Benedetti A, Riehm KE, Saadat N, Levis AW, Azar M et al. Probability of major depression diagnostic classification using semistructured versus fully structured diagnostic interviews. The British Journal of Psychiatry. 2018;212(6):377–85. DOI: 10.1192/bjp.2018.54

32. Kwapong YA, Boakye E, Khan SS, Honigberg MC, Martin SS, Oyeka CP et al. Association of Depression and Poor Mental Health With Cardiovascular Disease and Suboptimal Cardiovascular Health Among Young Adults in the United States. Journal of the American Heart Association. 2023;12(3):e028332. DOI: 10.1161/JAHA.122.028332

33. Bojanić I, Sund ER, Sletvold H, Bjerkeset O. Prevalence trends of depression and anxiety symptoms in adults with cardiovascular diseases and diabetes 1995–2019: The HUNT studies, Norway. BMC Psychology. 2021;9(1):130. DOI: 10.1186/s40359-021-00636-0

34. Погосова Н.В., Бойцов С.А., Оганов Р.Г., Юферева Ю.М., Костюк Г.П., Курсаков А.А. и др. Клинико-эпидемиОлогическая програМма изучЕния психосоциальных факТоров рискА в кардиологической практике у больных артериальной гипертонией и ишемической болезнью сердца (КОМЕТА): первые результаты российского многоцентрового исследования. Кардиология. 2018;58(9):47–58. DOI: 10.18087/cardio.2018.9.10171

35. Karami N, Kazeminia M, Karami A, Salimi Y, Ziapour A, Janjani P. Global prevalence of depression, anxiety, and stress in cardiac patients: A systematic review and meta-analysis. Journal of Affective Disorders. 2023;324:175–89. DOI: 10.1016/j.jad.2022.12.055

36. Gaffey AE, Gathright EC, Fletcher LM, Goldstein CM. Screening for Psychological Distress and Risk of Cardiovascular Disease and Related Mortality: A Systematized Review, Meta-analysis, and Case for Prevention. Journal of Cardiopulmonary Rehabilitation and Prevention. 2022;42(6):404–15. DOI: 10.1097/HCR.0000000000000751

37. Nakamura S, Kato K, Yoshida A, Fukuma N, Okumura Y, Ito H et al. Prognostic Value of Depression, Anxiety, and Anger in Hospitalized Cardiovascular Disease Patients for Predicting Adverse Cardiac Outcomes. The American Journal of Cardiology. 2013;111(10):1432–6. DOI: 10.1016/j.amjcard.2013.01.293

38. Fan AZ, Strine TW, Jiles R, Berry JT, Mokdad AH. Psychological distress, use of rehabilitation services, and disability status among noninstitutionalized US adults aged 35 years and older, who have cardiovascular conditions, 2007. International Journal of Public Health. 2009;54(Suppl 1):100–5. DOI: 10.1007/s00038-009-1313-2

39. Charlson FJ, Moran AE, Freedman G, Norman RE, Stapelberg NJ, Baxter AJ et al. The contribution of major depression to the global burden of ischemic heart disease: a comparative risk assessment. BMC Medicine. 2013;11(1):250. DOI: 10.1186/1741-7015-11-250

40. Bekelman DB, Havranek EP, Becker DM, Kutner JS, Peterson PN, Wittstein IS et al. Symptoms, Depression, and Quality of Life in Patients With Heart Failure. Journal of Cardiac Failure. 2007;13(8):643–8. DOI: 10.1016/j.cardfail.2007.05.005

41. Gravely-Witte S, De Gucht V, Heiser W, Grace SL, Van Elderen T. The impact of angina and cardiac history on health-related quality of life and depression in coronary heart disease patients. Chronic Illness. 2007;3(1):66–76. DOI: 10.1177/1742395307079192

42. Huang W, Aune D, Ferrari G, Zhang L, Lan Y, Nie J et al. Psychological Distress and All-Cause, Cardiovascular Disease, Cancer Mortality Among Adults with and without Diabetes. Clinical Epidemiology. 2021;13:555–65. DOI: 10.2147/CLEP.S308220

43. Meier SM, Mattheisen M, Mors O, Mortensen PB, Laursen TM, Penninx BW. Increased mortality among people with anxiety disorders: total population study. British Journal of Psychiatry. 2016;209(3):216–21. DOI: 10.1192/bjp.bp.115.171975

44. Zhang Z, Jackson SL, Gillespie C, Merritt R, Yang Q. Depressive Symptoms and Mortality Among US Adults. JAMA Network Open. 2023;6(10):e2337011. DOI: 10.1001/jamanetworkopen.2023.37011

45. Péquignot R, Dufouil C, Pérès K, Artero S, Tzourio C, Empana J. Depression Increases the Risk of Death Independently From Vascular Events in Elderly Individuals: The Three‐City Study. Journal of the American Geriatrics Society. 2019;67(3):546–52. DOI: 10.1111/jgs.15731

46. Shen R, Zhao N, Wang J, Guo P, Shen S, Liu D et al. Association between level of depression and coronary heart disease, stroke risk and all-cause and cardiovascular mortality: Data from the 2005–2018 National Health and Nutrition Examination Survey. Frontiers in Cardiovascular Medicine. 2022;9:954563. DOI: 10.3389/fcvm.2022.954563

47. Tian F, Shen Q, Hu Y, Ye W, Valdimarsdóttir UA, Song H et al. Association of stress-related disorders with subsequent risk of all-cause and cause-specific mortality: A population-based and sibling-controlled cohort study. The Lancet Regional Health - Europe. 2022;18:100402. DOI: 10.1016/j.lanepe.2022.100402

48. Mourad G, Lundgren J, Andersson G, Johansson P. Healthcare use in patients with cardiovascular disease and depressive symptoms – The impact of a nurseled internet-delivered cognitive behavioural therapy program. A secondary analysis of a RCT. Internet Interventions. 2024;35:100696. DOI: 10.1016/j.invent.2023.100696

49. Mourad G, Jaarsma T, Hallert C, Strömberg A. Depressive symptoms and healthcare utilization in patients with noncardiac chest pain compared to patients with ischemic heart disease. Heart & Lung. 2012;41(5):446–55. DOI: 10.1016/j.hrtlng.2012.04.002

50. Ni J, Yan Y, Du W, Tian Y, Fan L. Depressive symptoms, alone or together with physical comorbidity, are predictive of healthcare use and spending in older adults. Journal of Psychosomatic Research. 2023;174:111482. DOI: 10.1016/j.jpsychores.2023.111482

51. Stephenson JJ, Grabner M, Faries D, Palli SR, Robinson R. The impact of anxiety on Healthcare Utilization and costs among respondents from the Co-Morbidities and Symptoms of depression (CODE) study. Value in Health. 2015;18(3):A119. DOI: 10.1016/j.jval.2015.03.700

52. Horenstein A, Heimberg RG. Anxiety disorders and healthcare utilization: A systematic review. Clinical Psychology Review. 2020;81:101894. DOI: 10.1016/j.cpr.2020.101894

53. Seldenrijk A, Vogelzangs N, Batelaan NM, Wieman I, Van Schaik DJF, Penninx BJWH. Depression, anxiety and 6-year risk of cardiovascular disease. Journal of Psychosomatic Research. 2015;78(2):123–9. DOI: 10.1016/j.jpsychores.2014.10.007

54. Curth NK, Hjorthøj C, Brinck-Claussen U, Jørgensen KB, Rosendal S, Bojesen AB et al. The effects of collaborative care versus consultation liaison for anxiety disorders and depression in Denmark: two randomised controlled trials. The British Journal of Psychiatry. 2023;223(3):430–7. DOI: 10.1192/bjp.2023.77

55. Sighinolfi C, Nespeca C, Menchetti M, Levantesi P, Belvederi Murri M, Berardi D. Collaborative care for depression in European countries: A systematic review and meta-analysis. Journal of Psychosomatic Research. 2014;77(4):247–63. DOI: 10.1016/j.jpsychores.2014.08.006

56. Huffman JC, Mastromauro CA, Beach SR, Celano CM, DuBois CM, Healy BC et al. Collaborative Care for Depression and Anxiety Disorders in Patients With Recent Cardiac Events: The Management of Sadness and Anxiety in Cardiology (MOSAIC) Randomized Clinical Trial. JAMA Internal Medicine. 2014;174(6):927–36. DOI: 10.1001/jamainternmed.2014.739

57. Camacho EM, Ntais D, Coventry P, Bower P, Lovell K, Chew-Graham C et al. Long-term cost-effectiveness of collaborative care (vs usual care) for people with depression and comorbid diabetes or cardiovascular disease: a Markov model informed by the COINCIDE randomised controlled trial. BMJ Open. 2016;6(10):e012514. DOI: 10.1136/bmjopen-2016-012514

58. Richards DA, Bower P, Chew-Graham C, Gask L, Lovell K, Cape J et al. Clinical effectiveness and cost-effectiveness of collaborative care for depression in UK primary care (CADET): a cluster randomised controlled trial. Health Technology Assessment. 2016;20(14):1–192. DOI: 10.3310/hta20140

59. Краснов В.Н., Вельтищев Д.Ю., Бобров А.Е., Довженко Т.В. Расстройства аффективного спектра в общей медицинской практике (принципы терапии и партнерского взаимодействия психиатров и интернистов). Методические рекомендации. - М.: Национальный медицинский исследовательский центр психиатрии и наркологии имени В.П. Сербского; 2021. - 32с. ISBN 978-5-86002-303-1

60. Silverman JJ, Galanter M, Jackson-Triche M, Jacobs DG, Lomax JW, Riba MB et al. The American Psychiatric Association Practice Guidelines for the Psychiatric Evaluation of Adults. American Journal of Psychiatry. 2015;172(8):798–802. DOI: 10.1176/appi.ajp.2015.1720501

61. Correll CU, Galling B, Pawar A, Krivko A, Bonetto C, Ruggeri M et al. Comparison of Early Intervention Services vs Treatment as Usual for Early-Phase Psychosis: A Systematic Review, Meta-analysis, and Metaregression. JAMA Psychiatry. 2018;75(6):555–65. DOI: 10.1001/jamapsychiatry.2018.0623

62. Albert N, Melau M, Jensen H, Emborg C, Jepsen JRM, Fagerlund B et al. Five years of specialised early intervention versus two years of specialised early intervention followed by three years of standard treatment for patients with a first episode psychosis: randomised, superiority, parallel group trial in Denmark (OPUS II). BMJ. 2017;356:i6681. DOI: 10.1136/bmj.i6681

63. Fernández A, Pinto-Meza A, Bellón JA, Roura-Poch P, Haro JM, Autonell J et al. Is major depression adequately diagnosed and treated by general practitioners? Results from an epidemiological study. General Hospital Psychiatry. 2010;32(2):201–9. DOI: 10.1016/j.genhosppsych.2009.11.015

64. Siskind D, Araya R, Kim J. Cost-effectiveness of improved primary care treatment of depression in women in Chile. British Journal of Psychiatry. 2010;197(4):291–6. DOI: 10.1192/bjp.bp.109.068957

65. Katon W, Rutter C, Ludman EJ, Von Korff M, Lin E, Simon G et al. A Randomized Trial of Relapse Prevention of Depression in Primary Care. Archives of General Psychiatry. 2001;58(3):241–7. DOI: 10.1001/archpsyc.58.3.241

66. Trautman S, Beesdo-Baum K. The Treatment of Depression in Primary Care. Deutsches Ärzteblatt international. 2017;114(43):721–8. DOI: 10.3238/arztebl.2017.0721

67. Weisberg RB, Dyck I, Culpepper L, Keller MB. Psychiatric Treatment in Primary Care Patients With Anxiety Disorders: A Comparison of Care Received From Primary Care Providers and Psychiatrists. American Journal of Psychiatry. 2007;164(2):276–82. DOI: 10.1176/ajp.2007.164.2.276

68. Parker EL, Banfield M, Fassnacht DB, Hatfield T, Kyrios M. Contemporary treatment of anxiety in primary care: a systematic review and metaanalysis of outcomes in countries with universal healthcare. BMC Family Practice. 2021;22(1):92. DOI: 10.1186/s12875-021-01445-5

69. Bruce ML, Raue PJ, Reilly CF, Greenberg RL, Meyers BS, Banerjee S et al. Clinical Effectiveness of Integrating Depression Care Management Into Medicare Home Health: The Depression CAREPATH Randomized Trial. JAMA Internal Medicine. 2015;175(1):55–64. DOI: 10.1001/jamainternmed.2014.5835

70. Лебедева Е.В., Репин А.Н., Счастный Е.Д., Сергиенко Т.Н., Симуткин Г.Г., Горохов А.С. и др. Методическое пособие по организации работы междисциплинарной команды при реабилитации пациентов с хронической ишемической болезнью сердца и депрессивными расстройствами. – Томск: Иван Федоров; 2015. - 106с. ISBN 978-5-91701-104-2

71. Li M, Tang H, Liu X. Primary care team and its association with quality of care for people with multimorbidity: a systematic review. BMC Primary Care. 2023;24(1):20. DOI: 10.1186/s12875-023-01968-z

72. Chen JA, Macchiano S, Beckmann D, Chung W-J, Gartaganis S, Huffman JC. Implementing Multidisciplinary, Team-Based Care in an Academic Outpatient Psychiatry Department. Psychiatric Services. 2022;73(11):1290–3. DOI: 10.1176/appi.ps.202200030

73. Olfson M, Blanco C, Marcus SC. Treatment of Adult Depression in the United States. JAMA Internal Medicine. 2016;176(10):1482–91. DOI: 10.1001/jamainternmed.2016.5057

74. Jha MK, Qamar A, Vaduganathan M, Charney DS, Murrough JW. Screening and Management of Depression in Patients With Cardiovascular Disease: JACC State-of-the-Art Review. Journal of the American College of Cardiology. 2019;73(14):1827–45. DOI: 10.1016/j.jacc.2019.01.041

75. US Preventive Services Task Force, Barry MJ, Nicholson WK, Silverstein M, Chelmow D, Coker TR et al. Screening for Depression and Suicide Risk in Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2023;329(23):2057–67. DOI: 10.1001/jama.2023.9297

76. US Preventive Services Task Force, Barry MJ, Nicholson WK, Silverstein M, Coker TR, Davidson KW et al. Screening for Anxiety Disorders in Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2023;329(24):2163–70. DOI: 10.1001/jama.2023.9301

77. Золотарева А.А. Адаптация русскоязычной версии шкалы генерализованного тревожного расстройства (Generalized Anxiety Disorder-7). Консультативная психология и психотерапия. 2023;31(4):31–46. DOI: 10.17759/cpp.2023310402

78. Погосова Н.В., Довженко Т.В., Бабин А.Г., Курсаков А.А., Выгодин В.А. Русскоязычная версия опросников PHQ-2 и 9: чувствительность и специфичность при выявлении депрессии у пациентов общемедицинской амбулаторной практики. Кардиоваскулярная терапия и профилактика. 2014;13(3):18-24. DOI: 10.15829/1728-8800-2014-3-18-24

79. Морозова М.А., Потанин С.С., Бениашвили А.Г., Бурминский Д.С., Лепилкина Т.А., Рупчев Г.Е. и др. Валидация русскоязычной версии Госпитальной шкалы тревоги и депрессии в общей популяции. Профилактическая медицина. 2023;26(4):7-14. DOI: 10.17116/profmed2023260417

80. Irwing P, Booth T, Hughes DJ. The Wiley handbook of psychometric testing: a multidisciplinary reference on survey, scale and test development. - Hoboken (N.J.): Wiley Blackwell; 2018. - 1022p. ISBN 978-1-118-48977-2

81. Белялов Ф.И. Прогнозирование и шкалы в медицине. 4-е изд. – М.: ГЭОТАР-Медиа; 2023. - 416с. ISBN 978-5-9704-7307-8

82. Wu Y, Levis B, Sun Y, He C, Krishnan A, Neupane D et al. Accuracy of the Hospital Anxiety and Depression Scale Depression subscale (HADS-D) to screen for major depression: systematic review and individual participant data meta-analysis. BMJ. 2021;373:n972. DOI: 10.1136/bmj.n972

83. Levis B, Benedetti A, Thombs BD. Accuracy of Patient Health Questionnaire-9 (PHQ-9) for screening to detect major depression: individual participant data meta-analysis. BMJ. 2019;365:l1476. DOI: 10.1136/bmj.l1476

84. Plummer F, Manea L, Trepel D, McMillan D. Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic meta-analysis. General Hospital Psychiatry. 2016;39:24–31. DOI: 10.1016/j.genhosppsych.2015.11.005

85. Manea L, Gilbody S, McMillan D. A diagnostic meta-analysis of the Patient Health Question-naire-9 (PHQ-9) algorithm scoring method as a screen for depression. General Hospital Psychiatry. 2015;37(1):67–75. DOI: 10.1016/j.genhosppsych.2014.09.009

86. Christensen AV, Dixon JK, Juel K, Ekholm O, Rasmussen TB, Borregaard B et al. Psychometric properties of the Danish Hospital Anxiety and Depression Scale in patients with cardiac disease: results from the DenHeart survey. Health and Quality of Life Outcomes. 2020;18(1):9. DOI: 10.1186/s12955-019-1264-0

87. Thombs BD, Ziegelstein RC, Roseman M, Kloda LA, Ioannidis JP. There are no randomized controlled trials that support the United States Preventive Services Task Force guideline on screening for depression in primary care: a systematic review. BMC Medicine. 2014;12(1):13. DOI: 10.1186/1741-7015-12-13

88. Romera I, Montejo ÁL, Aragonés E, Arbesú JÁ, Iglesias-García C, López S et al. Systematic depression screening in high-risk patients attending primary care: a pragmatic cluster-randomized trial. BMC Psychiatry. 2013;13(1):83. DOI: 10.1186/1471-244X-13-83

89. Moore M, Ali S, Stuart B, Leydon GM, Ovens J, Goodall C et al. Depression management in primary care: an observational study of management changes related to PHQ-9 score for depression monitoring. British Journal of General Practice. 2012;62(599):e451–7. DOI: 10.3399/bjgp12X649151

90. Toussaint A, Hüsing P, Gumz A, Wingenfeld K, Härter M, Schramm E et al. Sensitivity to change and minimal clinically important difference of the 7-item Generalized Anxiety Disorder Questionnaire (GAD-7). Journal of Affective Disorders. 2020;265:395–401. DOI: 10.1016/j.jad.2020.01.032

91. Murphy B, Le Grande M, Alvarenga M, Worcester M, Jackson A. Anxiety and Depression After a Cardiac Event: Prevalence and Predictors. Frontiers in Psychology. 2020;10:3010. DOI: 10.3389/fpsyg.2019.03010

92. O’Connor EA, Henninger ML, Perdue LA, Coppola EL, Thomas RG, Gaynes BN. Anxiety Screening: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2023;329(24):2171–84. DOI: 10.1001/jama.2023.6369

93. Nimalasuriya K, Compton MT, Guillory VJ, Prevention Practice Committee of the American College of Preventive Medicine. Screening adults for depression in primary care: A position statement of the American College of Preventive Medicine. The Journal of Family Practice. 2009;58(10):535–8. PMID: 19874732

94. ICSI. Major Depression in Adults in Primary Care. 17th edition. 2016. 131p. Av. at: https://www.icsi.org/wp-content/uploads/2021/11/DeprES.pdf.

95. Adzrago D, Walker TJ, Williams F. Reliability and validity of the Patient Health Question-naire-4 scale and its subscales of depression and anxiety among US adults based on nativity. BMC Psychiatry. 2024;24(1):213. DOI: 10.1186/s12888-024-05665-8

96. Reavell J, Hopkinson M, Clarkesmith D, Lane DA. Effectiveness of Cognitive Behavioral Therapy for Depression and Anxiety in Patients With Cardiovascular Disease: A Systematic Review and Meta-Analysis. Psychosomatic Medicine. 2018;80(8):742–53. DOI: 10.1097/PSY.0000000000000626

97. Holdgaard A, Eckhardt-Hansen C, Lassen CF, Kjesbu IE, Dall CH, Michaelsen KL et al. Cognitive-behavioural therapy reduces psychological distress in younger patients with cardiac disease: a randomized trial. European Heart Journal. 2023;44(11):986–96. DOI: 10.1093/eurheartj/ehac792

98. El Baou C, Desai R, Cooper C, Marchant NL, Pilling S, Richards M et al. Psychological therapies for depression and cardiovascular risk: evidence from national healthcare records in England. European Heart Journal. 2023;44(18):1650–62. DOI: 10.1093/eurheartj/ehad188

99. Cuijpers P, Miguel C, Harrer M, Plessen CY, Ciharova M, Ebert D et al. Cognitive behavior therapy vs. control conditions, other psychotherapies, pharmacotherapies and combined treatment for depression: a comprehensive meta‐analysis including 409 trials with 52,702 patients. World Psychiatry. 2023;22(1):105–15. DOI: 10.1002/wps.21069

100. Ski CF, Taylor RS, McGuigan K, Long L, Lambert JD, Richards SH et al. Psychological interventions for depression and anxiety in patients with coronary heart disease, heart failure or atrial fibrillation. Cochrane Database of Systematic Reviews. 2024;2024(5):CD013508. DOI: 10.1002/14651858.CD013508.pub3

101. Ding N, Sang Y, Chen J, Ballew SH, Kalbaugh CA, Salameh MJ et al. Cigarette Smoking, Smoking Cessation, and Long-Term Risk of 3 Major Atherosclerotic Diseases. Journal of the American College of Cardiology. 2019;74(4):498–507. DOI: 10.1016/j.jacc.2019.05.049

102. Taylor GM, Lindson N, Farley A, Leinberger-Jabari A, Sawyer K, Te Water Naudé R et al. Smoking cessation for improving mental health. Cochrane Database of Systematic Reviews. 2021;2021(3):CD013522. DOI: 10.1002/14651858.CD013522.pub2

103. Wu AD, Lindson N, Hartmann-Boyce J, Wahedi A, Hajizadeh A, Theo doulou A et al. Smoking cessation for secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews. 2022;2022(8):CD014936. DOI: 10.1002/14651858.CD014936.pub2

104. Benowitz NL, Pipe A, West R, Hays JT, Tonstad S, McRae T et al. Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial. JAMA Internal Medicine. 2018;178(5):622–31. DOI: 10.1001/jamainternmed.2018.0397

105. Auer R, Schoeni A, Humair J-P, Jacot-Sadowski I, Berlin I, Stuber MJ et al. Electronic Nicotine-Delivery Systems for Smoking Cessation. New England Journal of Medicine. 2024;390(7):601–10. DOI: 10.1056/NEJMoa2308815

106. Lindson N, Butler AR, McRobbie H, Bullen C, Hajek P, Begh R et al. Electronic cigarettes for smoking cessation. Cochrane Database of Systematic Reviews. 2024;2024(1):CD010216. DOI: 10.1002/14651858.CD010216.pub8

107. Livingstone-Banks J, Fanshawe TR, Thomas KH, Theodoulou A, Hajizadeh A, Hartman L et al. Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews. 2023;2024(5):CD006103. DOI: 10.1002/14651858.CD006103.pub9

108. Rigotti NA, Benowitz NL, Prochaska J, Leischow S, Nides M, Blumenstein B et al. Cytisinicline for Smoking Cessation: A Randomized Clinical Trial. JAMA. 2023;330(2):152–60. DOI: 10.1001/jama.2023.10042

109. Tuisku A, Rahkola M, Nieminen P, Toljamo T. Electronic Cigarettes vs Varenicline for Smoking Cessation in Adults: A Randomized Clinical Trial. JAMA Internal Medicine. 2024;184(8):915–21. DOI: 10.1001/jamainternmed.2024.1822

110. Krittanawong C, Isath A, Rosenson RS, Khawaja M, Wang Z, Fogg SE et al. Alcohol Consumption and Cardiovascular Health. The American Journal of Medicine. 2022;135(10):1213-1230.e3. DOI: 10.1016/j.amjmed.2022.04.021

111. Biddinger KJ, Emdin CA, Haas ME, Wang M, Hindy G, Ellinor PT et al. Association of Habitual Alcohol Intake With Risk of Cardiovascular Disease. JAMA Network Open. 2022;5(3):e223849. DOI: 10.1001/jamanetworkopen.2022.3849

112. Millwood IY, Walters RG, Mei XW, Guo Y, Yang L, Bian Z et al. Conventional and genetic evidence on alcohol and vascular disease aetiology: a prospective study of 500 000 men and women in China. The Lancet. 2019;393(10183):1831–42. DOI: 10.1016/S01406736(18)31772-0

113. Holmes MV, Dale CE, Zuccolo L, Silverwood RJ, Guo Y, Ye Z et al. Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data. BMJ. 2014;349:g4164. DOI: 10.1136/bmj.g4164

114. Jayakody K, Gunadasa S, Hosker C. Exercise for anxiety disorders: systematic review. British Journal of Sports Medicine. 2014;48(3):187–96. DOI: 10.1136/bjsports-2012-091287

115. Hallgren M, Nguyen T-T-D, Herring MP, McDowell CP, Gordon BR, Stubbs B et al. Associations of physical activity with anxiety symptoms and disorders: Findings from the Swedish National March Cohort. General Hospital Psychiatry. 2019;58:45–50. DOI: 10.1016/j.genhosppsych.2019.03.001

116. Yu Q, Wong K-K, Lei O-K, Nie J, Shi Q, Zou L et al. Comparative Effectiveness of Multiple Exercise Interventions in the Treatment of Mental Health Disorders: A Systematic Review and Network Meta-Analysis. Sports Medicine - Open. 2022;8(1):135. DOI: 10.1186/s40798-022-00529-5

117. Cooney GM, Dwan K, Greig CA, Lawlor DA, Rimer J, Waugh FR et al. Exercise for depression. Cochrane Database of Systematic Reviews. 2013;2013(9):CD004366. DOI: 10.1002/14651858.CD004366.pub6

118. Gordon BR, McDowell CP, Hallgren M, Meyer JD, Lyons M, Herring MP. Association of Efficacy of Resistance Exercise Training With Depressive Symptoms: Meta-analysis and Meta-regression Analysis of Randomized Clinical Trials. JAMA Psychiatry. 2018;75(6):566–76. DOI: 10.1001/jamapsychiatry.2018.0572

119. Carmin CN, Ownby RL, Fontanella C, Steelesmith D, Binkley PF. Impact of Mental Health Treatment on Outcomes in Patients With Heart Failure and Ischemic Heart Disease. Journal of the American Heart Association. 2024;13(7):e031117. DOI: 10.1161/JAHA.123.031117

120. Van Dis EAM, Van Veen SC, Hagenaars MA, Batelaan NM, Bockting CLH, Van Den Heuvel RM et al. Long-term Outcomes of Cognitive Behavioral Therapy for Anxiety-Related Disorders: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2020;77(3):265–73. DOI: 10.1001/jamapsychiatry.2019.3986

121. Papola D, Ostuzzi G, Tedeschi F, Gastaldon C, Purgato M, Del Giovane C et al. Comparative efficacy and acceptability of psychotherapies for panic disorder with or without agoraphobia: systematic review and network meta-analysis of randomised controlled trials. The British Journal of Psychiatry. 2022;221(3):507–19. DOI: 10.1192/bjp.2021.148

122. Papola D, Miguel C, Mazzaglia M, Franco P, Tedeschi F, Romero SA et al. Psychotherapies for Generalized Anxiety Disorder in Adults: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials. JAMA Psychiatry. 2024;81(3):250–9. DOI: 10.1001/jamapsychiatry.2023.3971

123. Plessen CY, Karyotaki E, Miguel C, Ciharova M, Cuijpers P. Exploring the efficacy of psychotherapies for depression: a multiverse metaanalysis. BMJ Mental Health. 2023;26(1):e300626. DOI: 10.1136/bmjment-2022-300626

124. Kolovos S, Kleiboer A, Cuijpers P. Effect of psychotherapy for depression on quality of life: meta-analysis. British Journal of Psychiatry. 2016;209(6):460–8. DOI: 10.1192/bjp.bp.115.175059

125. Hofmann SG, Wu JQ, Boettcher H. Effect of cognitive-behavioral therapy for anxiety disorders on quality of life: A meta-analysis. Journal of Consulting and Clinical Psychology. 2014;82(3):375–91. DOI: 10.1037/a0035491

126. Karyotaki E, Efthimiou O, Miguel C, Maas Genannt Bermpohl F, Furukawa TA, Cuijpers P et al. Internet-Based Cognitive Behavioral Therapy for Depression: A Systematic Review and Individual Patient Data Network Meta-analysis. JAMA Psychiatry. 2021;78(4):361–71. DOI: 10.1001/jamapsychiatry.2020.4364

127. Hedman‐Lagerlöf E, Carlbring P, Svärdman F, Riper H, Cuijpers P, Andersson G. Therapist‐supported Internet‐based cognitive behaviour therapy yields similar effects as face‐to‐face therapy for psychiatric and somatic disorders: an updated systematic review and meta‐analysis. World Psychiatry. 2023;22(2):305–14. DOI: 10.1002/wps.21088

128. Ricci C, Wood A, Muller D, Gunter MJ, Agudo A, Boeing H et al. Alcohol intake in relation to non-fatal and fatal coronary heart disease and stroke: EPIC-CVD case-cohort study. BMJ. 2018;361:k934. DOI: 10.1136/bmj.k934

129. Pearce M, Garcia L, Abbas A, Strain T, Schuch FB, Golubic R et al. Association Between Physical Activity and Risk of Depression: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2022;79(6):550–9. DOI: 10.1001/jamapsychiatry.2022.0609

130. Jones ME, Campbell G, Patel D, Brunner E, Shatapathy CC, MurrayThomas T et al. Risk of Mortality (including Sudden Cardiac Death) and Major Cardiovascular Events in Users of Olanzapine and Other Antipsychotics: A Study with the General Practice Research Database. Cardiovascular Psychiatry and Neurology. 2013;2013:1–13. DOI: 10.1155/2013/647476

131. Wu C, Tsai Y, Tsai H. Antipsychotic Drugs and the Risk of Ventricular Arrhythmia and/or Sudden Cardiac Death: A Nation‐wide Case‐Crossover Study. Journal of the American Heart Association. 2015;4(2):e001568. DOI: 10.1161/JAHA.114.001568

132. Weeke P, Jensen A, Folke F, Gislason GH, Olesen JB, Fosbøl EL et al. Antipsychotics and Associated Risk of Out-of-Hospital Cardiac Arrest. Clinical Pharmacology & Therapeutics. 2014;96(4):490–7. DOI: 10.1038/clpt.2014.139

133. Белялов Ф.И. Лечение болезней в условиях коморбидности. 12-е изд. - М.: ГЭОТАР-Медиа; 2022. - 546с. ISBN 978-5-9704-6360-4

134. Piña IL, Di Palo KE, Ventura HO. Psychopharmacology and Cardiovascular Disease. Journal of the American College of Cardiology. 2018;71(20):2346–59. DOI: 10.1016/j.jacc.2018.03.458

135. Мосолов С.Н., Малин Д.И., Рывкин П.В., Сычев Д.А. Лекарственные взаимодействия препаратов, применяемых в психиатрической практике. Современная терапия психических расстройств. 2019:S1:2-33. DOI: 10.21265/PSYPH.2019.50.40828

136. Fanoe S, Kristensen D, Fink-Jensen A, Jensen HK, Toft E, Nielsen J et al. Risk of arrhythmia induced by psychotropic medications: a proposal for clinical management. European Heart Journal. 2014;35(20):1306–15. DOI: 10.1093/eurheartj/ehu100

137. Beach SR, Celano CM, Sugrue AM, Adams C, Ackerman MJ, Noseworthy PA et al. QT Prolongation, Torsades de Pointes, and Psychotropic Medications: A 5-Year Update. Psychosomatics. 2018;59(2):105–22. DOI: 10.1016/j.psym.2017.10.009

138. Castro VM, Clements CC, Murphy SN, Gainer VS, Fava M, Weilburg JB et al. QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ. 2013;346:f288. DOI: 10.1136/bmj.f288

139. Малин Д.И., Булатова Д.Р., Шустова Л.Ю., Гордеева Р.П. Распространенность и факторы риска синдрома удлинения интервала QT у пациентов городской психиатрической больницы. Современная терапия психических расстройств. 2023;3:50-6. DOI: 10.21265/PSYPH.2023.60.92.006

140. Kasper S, Gastpar M, Müller WE, Volz H-P, Möller H-J, Schläfke S et al. Lavender oil preparation Silexan is effective in generalized anxiety disorder – a randomized, double-blind comparison to placebo and paroxetine. The International Journal of Neuropsychopharmacology. 2014;17(06):859–69. DOI: 10.1017/S1461145714000017

141. Donelli D, Antonelli M, Bellinazzi C, Gensini GF, Firenzuoli F. Effects of lavender on anxiety: A systematic review and meta-analysis. Phytomedicine. 2019;65:153099. DOI: 10.1016/j.phymed.2019.153099

142. Zhao X, Zhang H, Wu Y, Yu C. The efficacy and safety of St. John’s wort extract in depression therapy compared to SSRIs in adults: A meta-analysis of randomized clinical trials. Advances in Clinical and Experimental Medicine. 2022;32(2):151–61. DOI: 10.17219/acem/152942

143. Cui YH, Zheng Y. A meta-analysis on the efficacy and safety of St John’s wort extract in depression therapy in comparison with selective serotonin reuptake inhibitors in adults. Neuro-psychiatric Disease and Treatment. 2016;12:1715–23. DOI: 10.2147/NDT.S106752

144. Sartorius N, Baghai TC, Baldwin DS, Barrett B, Brand U, Fleischhacker W et al. Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence. The International Journal of Neuropsychopharmacology. 2007;10(Suppl 1):S1-207. DOI: 10.1017/S1461145707008255

145. Baldwin DS, Stein DJ, Dolberg OT, Bandelow B. How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database. Human Psychopharmacology: Clinical and Experimental. 2009;24(4):269–75. DOI: 10.1002/hup.1019

146. De Vries YA, Roest AM, Bos EH, Burgerhof JGM, Van Loo HM, De Jonge P. Predicting antidepressant response by monitoring early improvement of individual symptoms of depression: individual patient data meta-analysis. British Journal of Psychiatry. 2019;214(1):4–10. DOI: 10.1192/bjp.2018.122

147. Cleare A, Pariante C, Young A, Anderson I, Christmas D, Cowen P et al. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. Journal of Psychopharmacology. 2015;29(5):459–525. DOI: 10.1177/0269881115581093

148. Nochaiwong S, Ruengorn C, Awiphan R, Chai-Adisaksopha C, Tantraworasin A, Phosuya C et al. Use of serotonin reuptake inhibitor antidepressants and the risk of bleeding complications in patients on anticoagulant or antiplatelet agents: a systematic review and meta-analysis. Annals of Medicine. 2022;54(1):80–97. DOI: 10.1080/07853890.2021.2017474

149. Laporte S, Chapelle C, Caillet P, Beyens M-N, Bellet F, Delavenne X et al. Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: A meta-analysis of observational studies. Pharmacological Research. 2017;118:19–32. DOI: 10.1016/j.phrs.2016.08.017

150. Montastruc J-L, Bura-Rivière A. Association of antidepressants plus antithrombotics and bleeding risk: a pharmacovigilance study. European Journal of Clinical Pharmacology. 2024;80(2):283–5. DOI: 10.1007/s00228-023-03590-5

151. Axelsson MAB, Tukukino C, Parodi López N, Wallerstedt SM. Bleeding in patients on concurrent treatment with a selective serotonin reuptake inhibitor (SSRI) and low‐dose acetylsalicylic acid (ASA) compared with SSRI or low‐dose ASA alone – A systematic review and meta‐analysis. British Journal of Clinical Pharmacology. 2024;90(4):916–32. DOI: 10.1111/bcp.16000

152. Perahia DG, Bangs ME, Zhang Q, Cheng Y, Ahl J, Frakes E et al. The risk of bleeding with duloxetine treatment in patients who use nonsteroidal anti-inflammatory drugs (NSAIDs): analysis of placebo-controlled trials and post-marketing adverse event reports. Drug, Healthcare and Patient Safety. 2013;5:211–9. DOI: 10.2147/DHPS. S45445

153. Rahman AA, Platt RW, Beradid S, Boivin J-F, Rej S, Renoux C. Concomitant Use of Selective Serotonin Reuptake Inhibitors With Oral Anticoagulants and Risk of Major Bleeding. JAMA Network Open. 2024;7(3):e243208. DOI: 10.1001/jamanetworkopen.2024.3208

154. Gandhi S, Shariff SZ, Al-Jaishi A, Reiss JP, Mamdani MM, Hackam DG et al. Second-Generation Antidepressants and Hyponatremia Risk: A Population-Based Cohort Study of Older Adults. American Journal of Kidney Diseases. 2017;69(1):87–96. DOI: 10.1053/j.ajkd.2016.08.020

155. Viramontes TS, Truong H, Linnebur SA. Antidepressant-Induced Hyponatremia in Older Adults. The Consultant Pharmacist. 2016;31(3):139–50. DOI: 10.4140/TCP.n.2016.139

156. Gheysens T, Van Den Eede F, De Picker L. The risk of antidepressantinduced hyponatremia: A meta-analysis of antidepressant classes and compounds. European Psychiatry. 2024;67(1):e20. DOI: 10.1192/j.eurpsy.2024.11

157. Ojero-Senard A, Benevent J, Bondon-Guitton E, Durrieu G, Chebane L, Araujo M et al. A comparative study of QT prolongation with serotonin reuptake inhibitors. Psychopharmacology. 2017;234(20):3075–81. DOI: 10.1007/s00213-017-4685-7

158. Funk KA, Bostwick JR. A Comparison of the Risk of QT Prolongation Among SSRIs. Annals of Pharmacotherapy. 2013;47(10):1330–41. DOI: 10.1177/1060028013501994

159. Beach SR, Kostis WJ, Celano CM, Januzzi JL, Ruskin JN, Noseworthy PA et al. Meta-Analysis of Selective Serotonin Reuptake Inhibitor–Associated QTc Prolongation. The Journal of Clinical Psychiatry. 2014;75(5):e441–9. DOI: 10.4088/JCP.13r08672

160. Van Leeuwen E, Van Driel ML, Horowitz MA, Kendrick T, Donald M, De Sutter AI et al. Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults. Cochrane Database of Systematic Reviews. 2021;2021(4):CD013495. DOI: 10.1002/14651858.CD013495.pub2

161. Cohen D, Recalt A. Discontinuing Psychotropic Drugs from Participants in Randomized Controlled Trials: A Systematic Review. Psychotherapy and Psychosomatics. 2019;88(2):96–104. DOI: 10.1159/000496733

162. Хасанова А.К., Мосолов С.Н. Синдромом отмены приема антидепрессантов (алгоритм профилактики и коррекции). Современная терапия психических расстройств. 2023;2:37–47. DOI: 10.21265/PSYPH.2023.15.79.005

163. NICE. Generalised anxiety disorder and panic disorder in adults: management. - London: NICE; 2019. - 43p. ISBN 978-1-4731-2854-5

164. De Las Cuevas C, Sanz E, De La Fuente J. Benzodiazepines: more ‘behavioural’ addiction than dependence. Psychopharmacology. 2003;167(3):297–303. DOI: 10.1007/s00213-002-1376-8

165. Donnelly K, Bracchi R, Hewitt J, Routledge PA, Carter B. Benzodiazepines, Z-drugs and the risk of hip fracture: A systematic review and meta-analysis. PLOS ONE. 2017;12(4):e0174730. DOI: 10.1371/journal.pone.0174730

166. Poly TN, Islam MdM, Yang H-C, Li Y-C (Jack). Association between benzodiazepines use and risk of hip fracture in the elderly people: A meta-analysis of observational studies. Joint Bone Spine. 2020;87(3):241–9. DOI: 10.1016/j.jbspin.2019.11.003

167. Burschinski A, Schneider‐Thoma J, Chiocchia V, Schestag K, Wang D, Siafis S et al. Metabolic side effects in persons with schizophrenia during mid‐ to long‐term treatment with antipsychotics: a network meta‐analysis of randomized controlled trials. World Psychiatry. 2023;22(1):116–28. DOI: 10.1002/wps.21036

168. Erickson SC, Le L, Zakharyan A, Stockl KM, Harada ASM, Borson S et al. New‐Onset Treatment‐Dependent Diabetes Mellitus and Hyperlipidemia Associated with Atypical Antipsychotic Use in Older Adults without Schizophrenia or Bipolar Disorder. Journal of the American Geriatrics Society. 2012;60(3):474–9. DOI: 10.1111/j.1532-5415.2011.03842.x

169. Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. The Lancet. 2019;394(10202):939–51. DOI: 10.1016/S0140-6736(19)31135-3

170. Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. The Lancet Psychiatry. 2020;7(1):64–77. DOI: 10.1016/S2215-0366(19)30416-X

171. Wu H, Siafis S, Hamza T, Schneider-Thoma J, Davis JM, Salanti G et al. Antipsychotic-Induced Weight Gain: Dose-Response MetaAnalysis of Randomized Controlled Trials. Schizophrenia Bulletin. 2022;48(3):643–54. DOI: 10.1093/schbul/sbac001

172. Whicher CA, Price HC, Holt RIG. Mechanisms in endocrinology: Antipsychotic medication and type 2 diabetes and impaired glucose regulation. European Journal of Endocrinology. 2018;178(6):R245–58. DOI: 10.1530/EJE-18-0022

173. Ono S, Someya T. Lipid Metabolism Disturbances During Antipsychotic Treatment for Schizophrenia. P.987-1004. DOI: 10.1007/9783-030-62059-2_402. In: NeuroPsychopharmacotherapy. - Cham: Springer International Publishing; 2022. ISBN: 978-3-030-62058-5

174. Correll CU, Solmi M, Veronese N, Bortolato B, Rosson S, Santonastaso P et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large‐scale meta‐analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry. 2017;16(2):163–80. DOI: 10.1002/wps.20420

175. Zivkovic S, Koh CH, Kaza N, Jackson CA. Antipsychotic drug use and risk of stroke and myocardial infarction: a systematic review and meta-analysis. BMC Psychiatry. 2019;19(1):189. DOI: 10.1186/s12888-019-2177-5

176. Ray WA, Stein CM, Murray KT, Fuchs DC, Patrick SW, Daugherty J et al. Association of Antipsychotic Treatment With Risk of Unexpected Death Among Children and Youths. JA-MA Psychiatry. 2019;76(2):162–71. DOI: 10.1001/jamapsychiatry.2018.3421

177. Suvisaari J, Partti K, Perälä J, Viertiö S, Saarni SE, Lönnqvist J et al. Mortality and Its Determinants in People With Psychotic Disorder. Psychosomatic Medicine. 2013;75(1):60–7. DOI: 10.1097/PSY.0b013e31827ad512

178. Salvo F, Pariente A, Shakir S, Robinson P, Arnaud M, Thomas S et al. Sudden cardiac and sudden unexpected death related to antipsychotics: A meta‐analysis of observational studies. Clinical Pharmacology & Therapeutics. 2016;99(3):306–14. DOI: 10.1002/cpt.250

179. Huang K-L, Fang C-J, Hsu C-C, Wu S-I, Juang JJ, Stewart R. Myocardial infarction risk and antipsychotics use revisited: a meta-analysis of 10 observational studies. Journal of Psychopharmacology. 2017;31(12):1544–55. DOI: 10.1177/0269881117714047

180. Yu Z, Jiang H, Shao L, Zhou Y, Shi H, Ruan B. Use of antipsychotics and risk of myocardial infarction: a systematic review and meta‐analysis. British Journal of Clinical Pharmacology. 2016;82(3):624–32. DOI: 10.1111/bcp.12985

181. Almuwaqqat Z, Jokhadar M, Norby FL, Lutsey PL, O’Neal WT, Seyerle A et al. Association of Antidepressant Medication Type With the Incidence of Cardiovascular Disease in the ARIC Study. Journal of the American Heart Association. 2019;8(11):e012503. DOI: 10.1161/JAHA.119.012503

182. Coupland C, Hill T, Morriss R, Moore M, Arthur A, HippisleyCox J. Antidepressant use and risk of cardiovascular outcomes in people aged 20 to 64: cohort study using primary care database. BMJ. 2016;352:i1350. DOI: 10.1136/bmj.i1350

183. Mease PJ, Zimetbaum PJ, Duh MS, Vekeman F, Guérin A, Boerstoel-Streefland M et al. Epidemiologic Evaluation of Cardiovascular Risk in Patients Receiving Milnacipran, Venlafaxine, or Amitriptyline: Evidence from French Health Data. Annals of Pharmacotherapy. 2011;45(2):179–88. DOI: 10.1345/aph.1P391

184. Maslej MM, Bolker BM, Russell MJ, Eaton K, Durisko Z, Hollon SD et al. The Mortality and Myocardial Effects of Antidepressants Are Moderated by Preexisting Cardiovascular Disease: A Meta-Analysis. Psychotherapy and Psychosomatics. 2017;86(5):268–82. DOI: 10.1159/000477940

185. Kim JH, Song Y-K, Jang HY, Shin J-Y, Lee H-Y, Ahn YM et al. Major Adverse Cardiovascular Events in Antidepressant Users Within Patients With Ischemic Heart Diseases: A Nationwide Cohort Study. Journal of Clinical Psychopharmacology. 2020;40(5):475–81. DOI: 10.1097/JCP.0000000000001252

186. Cheng Y-L, Hu H-Y, Lin X-H, Luo J-C, Peng Y-L, Hou M-C et al. Use of SSRI, But Not SNRI, Increased Upper and Lower Gastrointestinal Bleeding: A Nationwide Population-Based Cohort Study in Taiwan. Medicine. 2015;94(46):e2022. DOI: 10.1097/MD.0000000000002022

187. De Abajo FJ, García-Rodríguez LA. Risk of Upper Gastrointestinal Tract Bleeding Associated With Selective Serotonin Reuptake Inhibitors and Venlafaxine Therapy: Interaction With Nonsteroidal Anti-inflammatory Drugs and Effect of Acid-Suppressing Agents. Archives of General Psychiatry. 2008;65(7):795–803. DOI: 10.1001/archpsyc.65.7.795

188. Andersson NW, Wohlfahrt J, Feenstra B, Hviid A, Melbye M, Lund M. Cumulative Incidence of Thiazide-Induced Hyponatremia: A Population-Based Cohort Study. Annals of Internal Medicine. 2024;177(1):1–11. DOI: 10.7326/M23-1989

189. Lane NE, Bai L, Seitz DP, Juurlink DN, Paterson JM, Guan J et al. Hyponatremia‐associated hospital visits are not reduced by early electrolyte testing in older adults starting antidepressants. Journal of the American Geriatrics Society. 2024;72(6):1770–80. DOI: 10.1111/jgs.18930

190. Jang HY, Kim JH, Song Y-K, Shin J-Y, Lee H-Y, Ahn YM et al. Antidepressant Use and the Risk of Major Adverse Cardiovascular Events in Patients Without Known Cardiovascular Disease: A Retrospective Cohort Study. Frontiers in Pharmacology. 2020;11:594474. DOI: 10.3389/fphar.2020.594474

191. Хасанова А.К. Применение антидепрессантов и риск падения у пациентов старшего возраста. Современная терапия психических расстройств. 2022;4:25–33. DOI: 10.21265/PSYPH.2022.74.75.004

192. Henssler J, Schmidt Y, Schmidt U, Schwarzer G, Bschor T, Baethge C. Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis. The Lancet Psychiatry. 2024;11(7):526–35. DOI: 10.1016/S2215-0366(24)00133-0

193. AlDawsari A, Bushell TJ, Abutheraa N, Sakata S, Al Hussain S, Kurdi A. Use of sedative‐hypnotic medications and risk of dementia: A systematic review and meta‐analysis. British Journal of Clinical Pharmacology. 2022;88(4):1567–89. DOI: 10.1111/bcp.15113

194. Osler M, Jørgensen MB. Associations of Benzodiazepines, Z-Drugs, and Other Anxiolytics With Subsequent Dementia in Patients With Affective Disorders: A Nationwide Cohort and Nested Case-Control Study. American Journal of Psychiatry. 2020;177(6):497–505. DOI: 10.1176/appi.ajp.2019.19030315

195. Hoskins MD, Bridges J, Sinnerton R, Nakamura A, Underwood JFG, Slater A et al. Pharmacological therapy for post-traumatic stress disorder: a systematic review and meta-analysis of monotherapy, augmentation and head-to-head approaches. European Journal of Psychotraumatology. 2021;12(1):1802920. DOI: 10.1080/20008198.2020.1802920

196. Komossa K, Depping AM, Meyer M, Kissling W, Leucht S. Secondgeneration antipsychotics for obsessive compulsive disorder. Cochrane Database of Systematic Reviews. 2010;12:CD008121. DOI: 10.1002/14651858.CD008141.pub2

197. Depping AM, Komossa K, Kissling W, Leucht S. Second-generation antipsychotics for anxiety disorders. Cochrane Database of Systematic Reviews. 2010;12:CD008120. DOI: 10.1002/14651858.CD008120.pub2

198. Министерство здравоохранения Российской Федерации. Российское общество психиатров. Шизофрения. 2024. 133 с. Доступно на: https://cr.minzdrav.gov.ru/preview-cr/451_3

199. Министерство здравоохранения Российской Федерации. Российское общество психиатров. Биполярное аффективное расстройство. 2021. 161 с. Доступно на: https://cr.minzdrav.gov.ru/preview-cr/675_1

200. Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH et al. Risk of Death in Elderly Users of Conventional vs. Atypical Antipsychotic Medications. New England Journal of Medicine. 2005;353(22):2335–41. DOI: 10.1056/NEJMoa052827

201. Hasnain M, Vieweg WVR. QTc Interval Prolongation and Torsade de Pointes Associated with Second-Generation Antipsychotics and Antidepressants: A Comprehensive Review. CNS Drugs. 2014;28(10):887–920. DOI: 10.1007/s40263-014-0196-9

202. Mok PLH, Carr MJ, Guthrie B, Morales DR, Sheikh A, Elliott RA et al. Multiple adverse outcomes associated with antipsychotic use in people with dementia: population based matched cohort study. BMJ. 2024;385:e076268. DOI: 10.1136/bmj-2023-076268

203. Yunusa I, Alsumali A, Garba AE, Regestein QR, Eguale T. Assessment of Reported Comparative Effectiveness and Safety of Atypical Antipsychotics in the Treatment of Behavioral and Psychological Symptoms of Dementia: A Network Meta-analysis. JAMA Network Open. 2019;2(3):e190828. DOI: 10.1001/jamanetworkopen.2019.0828

204. Yunusa I, Rashid N, Demos GN, Mahadik BS, Abler VC, Rajagopalan K. Comparative Outcomes of Commonly Used Off-Label Atypical Antipsychotics in the Treatment of Dementia-Related Psychosis: A Network Meta-analysis. Advances in Therapy. 2022;39(5):1993–2008. DOI: 10.1007/s12325-022-02075-8

205. Медведев В.Э. Алимемазин в психиатрии и психосоматике. Психиатрия и психофармакотерапия. 2018;20(3-4):26-33

206. Tan H, Yan X, Chen Y, Huang G, Luo L, Li W et al. A real-world pharmacovigilance study of drug-induced QT interval prolongation: analysis of spontaneous reports submitted to FAERS. Frontiers in Cardiovascular Medicine. 2024;11:1363382. DOI: 10.3389/fcvm.2024.1363382

207. Olariu E, Forero CG, Castro-Rodriguez JI, Rodrigo-Calvo MT, Álvarez P, Martín-López LM et al. Detection of anxiety disorders in primary care: a meta-analysis of assisted and unassisted diagnoses. Depression and Anxiety. 2015;32(7):471–84. DOI: 10.1002/da.22360

208. Незнанов Н.Г., Мартынихин И.А., Мосолов С.Н. Диагностика и терапия тревожных расстройств в Российской Федерации: результаты опроса врачей психиатров. Современная терапия психических расстройств. 2017;2:2-13. DOI: 10.21265/PSYPH.2017.41.6437

209. McGrath JJ, Al-Hamzawi A, Alonso J, Altwaijri Y, Andrade LH, Bromet EJ et al. Age of onset and cumulative risk of mental disorders: a cross-national analysis of population surveys from 29 countries. The Lancet Psychiatry. 2023;10(9):668–81. DOI: 10.1016/S2215-0366(23)00193-1

210. Bandelow B, Werner AM, Kopp I, Rudolf S, Wiltink J, Beutel ME. The German Guidelines for the treatment of anxiety disorders: first revision. European Archives of Psychiatry and Clinical Neuroscience. 2022;272(4):571–82. DOI: 10.1007/s00406-021-01324-1

211. Bandelow B, Reitt M, Röver C, Michaelis S, Görlich Y, Wedekind D. Efficacy of treatments for anxiety disorders: a meta-analysis. International Clinical Psychopharmacology. 2015;30(4):183–92. DOI: 10.1097/YIC.0000000000000078

212. Furukawa TA, Watanabe N, Churchill R. Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia. Cochrane Database of Systematic Reviews. 2007;1:CD004364. DOI: 10.1002/14651858.CD004364.pub2

213. Carpenter JK, Andrews LA, Witcraft SM, Powers MB, Smits JAJ, Hofmann SG. Cognitive behavioral therapy for anxiety and related disorders: A meta‐analysis of randomized placebo‐controlled trials. Depression and Anxiety. 2018;35(6):502–14. DOI: 10.1002/da.22728

214. Bolgeo T, Di Matteo R, Simonelli N, Dal Molin A, Lusignani M, Bassola B et al. Psychometric properties and measurement invariance of the 7-item General Anxiety Disorder scale (GAD-7) in an Italian coronary heart disease population. Journal of Affective Disorders. 2023;334:213–9. DOI: 10.1016/j.jad.2023.04.140

215. Guaiana G, Meader N, Barbui C, Davies SJ, Furukawa TA, Imai H et al. Pharmacological treatments in panic disorder in adults: a network meta-analysis. Cochrane Database of Systematic Reviews. 2023;11:CD012729. DOI: 10.1002/14651858.CD012729.pub3

216. Slee A, Nazareth I, Bondaronek P, Liu Y, Cheng Z, Freemantle N. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. The Lancet. 2019;393(10173):768–77. DOI: 10.1016/S0140-6736(18)31793-8

217. Generoso MB, Trevizol AP, Kasper S, Cho HJ, Cordeiro Q, Shiozawa P. Pregabalin for generalized anxiety disorder: an updated systematic review and meta-analysis. International Clinical Psychopharmacology. 2017;32(1):49–55. DOI: 10.1097/YIC.0000000000000147

218. Carl E, Witcraft SM, Kauffman BY, Gillespie EM, Becker ES, Cuijpers P et al. Psychological and pharmacological treatments for generalized anxiety disorder (GAD): a meta-analysis of randomized controlled trials. Cognitive Behaviour Therapy. 2020;49(1):1–21. DOI: 10.1080/16506073.2018.1560358

219. Stubbs B, Vancampfort D, Rosenbaum S, Firth J, Cosco T, Veronese N et al. An examination of the anxiolytic effects of exercise for people with anxiety and stress-related disorders: A meta-analysis. Psychiatry Research. 2017;249:102–8. DOI: 10.1016/j.psychres.2016.12.020

220. Ramos-Sanchez CP, Schuch FB, Seedat S, Louw QA, Stubbs B, Rosenbaum S et al. The anxiolytic effects of exercise for people with anxiety and related disorders: An update of the available meta-analytic evidence. Psychiatry Research. 2021;302:114046. DOI: 10.1016/j.psychres.2021.114046

221. Rebar AL, Stanton R, Geard D, Short C, Duncan MJ, Vandelanotte C. A meta-meta-analysis of the effect of physical activity on depression and anxiety in non-clinical adult populations. Health Psychology Review. 2015;9(3):366–78. DOI: 10.1080/17437199.2015.1022901

222. Donovan MR, Glue P, Kolluri S, Emir B. Comparative efficacy of antidepressants in preventing relapse in anxiety disorders – A metaanalysis. Journal of Affective Disorders. 2010;123(1–3):9–16. DOI: 10.1016/j.jad.2009.06.021

223. Batelaan NM, Bosman RC, Muntingh A, Scholten WD, Huijbregts KM, Van Balkom AJLM. Risk of relapse after antidepressant discontinuation in anxiety disorders, obsessive-compulsive disorder, and posttraumatic stress disorder: systematic review and meta-analysis of relapse prevention trials. BMJ. 2017;358:j3927. DOI: 10.1136/bmj.j3927

224. Perna G, Alciati A, Riva A, Micieli W, Caldirola D. Long-Term Pharmacological Treatments of Anxiety Disorders: An Updated Systematic Review. Current Psychiatry Reports. 2016;18(3):23. DOI: 10.1007/s11920-016-0668-3

225. Nelson HD, Cantor A, Pappas M, Weeks C. Screening for Anxiety in Adolescent and Adult Women: A Systematic Review for the Women’s Preventive Services Initiative. Annals of Internal Medicine. 2020;173(1):29–41. DOI: 10.7326/M20-0579

226. Guaiana G, Barbui C, Cipriani A. Hydroxyzine for generalised anxiety disorder. Cochrane Database of Systematic Reviews. 2010;12:CD006815. DOI: 10.1002/14651858.CD006815.pub2

227. Breilmann J, Girlanda F, Guaiana G, Barbui C, Cipriani A, Castellazzi M et al. Benzodiazepines versus placebo for panic disorder in adults. Cochrane Database of Systematic Reviews. 2019;3:CD010677. DOI: 10.1002/14651858.CD010677.pub2

228. Guerlais M, Grall-Bronnec M, Feuillet F, Gérardin M, Jolliet P, Victorri-Vigneau C. Dependence on Prescription Benzodiazepines and Zdrugs Among Young to Middle-aged Patients in France. Substance Use & Misuse. 2015;50(3):320–7. DOI: 10.3109/10826084.2014.980952

229. Martin JLR, Sainz-Pardo M, Furukawa TA, Martin-Sanchez E, Seoane T, Galan C. Review: Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials. Journal of Psychopharmacology. 2007;21(7):774–82. DOI: 10.1177/0269881107077355

230. Shinfuku M, Kishimoto T, Uchida H, Suzuki T, Mimura M, Kikuchi T. Effectiveness and safety of long-term benzodiazepine use in anxiety disorders: a systematic review and meta-analysis. International Clinical Psychopharmacology. 2019;34(5):211–21. DOI: 10.1097/YIC.0000000000000276

231. Teppo K, Jaakkola J, Airaksinen KEJ, Biancari F, Halminen O, Putaala J et al. Mental Health Conditions and Nonpersistence of Direct Oral Anticoagulant Use in Patients With Incident Atrial Fibrillation: A Nationwide Cohort Study. Journal of the American Heart Association. 2022;11(6):e024119. DOI: 10.1161/JAHA.121.024119

232. Dempe C, Jünger J, Hoppe S, Katzenberger M-L, Möltner A, Ladwig K-H et al. Association of anxious and depressive symptoms with medication nonadherence in patients with stable coronary artery disease. Journal of Psychosomatic Research. 2013;74(2):122–7. DOI: 10.1016/j.jpsychores.2012.12.003

233. Фомичева А.В., Трошина Д.В., Симонов А.Н., Копылов Ф.Ю., Андреев Д.А., Волель Б.А. Влияние тревожных расстройств на приверженность антикоагулянтной терапии у пациентов с фибрилляцией предсердий. Терапевтический архив. 2022;94(9):1085-93. DOI: 10.26442/0040366 0.2022.09.201891

234. Hu Z-C, Liu S-Y, Wu L-M, Shen L-S, Liu L-M, Li G-L et al. Factors influencing adherence to non-vitamin K antagonist oral anticoagulants in the early period after atrial fibrillation catheter ablation in China. Chinese Medical Journal. 2020;133(16):1989–91. DOI: 10.1097/CM9.0000000000001000

235. Kuhl EA, Fauerbach JA, Bush DE, Ziegelstein RC. Relation of Anxiety and Adherence to Risk-Reducing Recommendations Following Myocardial Infarction. The American Journal of Cardiology. 2009;103(12):1629–34. DOI: 10.1016/j.amjcard.2009.02.014

236. Baldwin D, Woods R, Lawson R, Taylor D. Efficacy of drug treatments for generalised anxiety disorder: systematic review and metaanalysis. BMJ. 2011;342:d1199. DOI: 10.1136/bmj.d1199

237. Kim H, Kim EJ. Effects of Relaxation Therapy on Anxiety Disorders: A Systematic Review and Meta-analysis. Archives of Psychiatric Nursing. 2018;32(2):278–84. DOI: 10.1016/j.apnu.2017.11.015

238. Daveney J, Panagioti M, Waheed W, Esmail A. Unrecognized bipolar disorder in patients with depression managed in primary care: A systematic review and meta-analysis. General Hospital Psychiatry. 2019;58:71–6. DOI: 10.1016/j.genhosppsych.2019.03.006

239. Cerimele JM, Chwastiak LA, Dodson S, Katon WJ. The Prevalence of Bipolar Disorder in Primary Care Patients With Depression or Other Psychiatric Complaints: A Systematic Review. Psychosomatics. 2013;54(6):515–24. DOI: 10.1016/j.psym.2013.05.009

240. Мосолов С.Н., Ушкалова А.В., Костюкова Е.Г., Шафаренко А.А., Алфимов П.В., Костюкова А.Б. Диагностика биполярного аффективного расстройства II типа среди пациентов с текущим диагнозом рекуррентного депрессивного расстройства. Современная терапия психических расстройств. 2014;2:2-12

241. Yildiz A, Siafis S, Mavridis D, Vieta E, Leucht S. Comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: a systematic review and network meta-analysis. The Lancet Psychiatry. 2023;10(9):693–705. DOI: 10.1016/S2215-0366(23)00199-2

242. Gartlehner G, Dobrescu A, Chapman A, Toromanova A, Emprechtinger R, Persad E et al. Nonpharmacologic and Pharmacologic Treatments of Adult Patients With Major Depressive Disorder: A Systematic Review and Network Meta-analysis for a Clinical Guideline by the American College of Physicians. Annals of Internal Medicine. 2023;176(2):196–211. DOI: 10.7326/M22-1845

243. Cuijpers P, Oud M, Karyotaki E, Noma H, Quero S, Cipriani A et al. Psychologic Treatment of Depression Compared With Pharmacotherapy and Combined Treatment in Primary Care: A Network MetaAnalysis. The Annals of Family Medicine. 2021;19(3):262–70. DOI: 10.1370/afm.2676

244. Amick HR, Gartlehner G, Gaynes BN, Forneris C, Asher GN, Morgan LC et al. Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis. BMJ. 2015;351:h6019. DOI: 10.1136/bmj.h6019

245. Bockting CLH, Klein NS, Elgersma HJ, Van Rijsbergen GD, Slofstra C, Ormel J et al. Effectiveness of preventive cognitive therapy while tapering antidepressants versus maintenance antidepressant treatment versus their combination in prevention of depressive relapse or recurrence (DRD study): a three-group, multicentre, randomised controlled trial. The Lancet Psychiatry. 2018;5(5):401–10. DOI: 10.1016/S2215-0366(18)30100-7

246. Krijnen-de Bruin E, Scholten W, Muntingh A, Maarsingh O, Van Meijel B, Van Straten A et al. Psychological interventions to prevent relapse in anxiety and depression: A systematic review and metaanalysis. PLOS ONE. 2022;17(8):e0272200. DOI: 10.1371/journal.pone.0272200

247. Kuyken W, Hayes R, Barrett B, Byng R, Dalgleish T, Kessler D et al. Effectiveness and cost-effectiveness of mindfulness-based cognitive therapy compared with maintenance antidepressant treatment in the prevention of depressive relapse or recurrence (PREVENT): a randomised controlled trial. The Lancet. 2015;386(9988):63–73. DOI: 10.1016/S0140-6736(14)62222-4

248. Breedvelt JJF, Brouwer ME, Harrer M, Semkovska M, Ebert DD, Cuijpers P et al. Psychological interventions as an alternative and add-on to antidepressant medication to prevent depressive relapse: systematic review and meta-analysis. The British Journal of Psychiatry. 2021;219(4):538–45. DOI: 10.1192/bjp.2020.198

249. Breedvelt JJF, Warren FC, Segal Z, Kuyken W, Bockting CL. Continuation of Antidepressants vs Sequential Psychological Interventions to Prevent Relapse in Depression: An Individual Participant Data Metaanalysis. JAMA Psychiatry. 2021;78(8):868–75. DOI: 10.1001/jamapsychiatry.2021.0823

250. Cuijpers P, Noma H, Karyotaki E, Vinkers CH, Cipriani A, Furukawa TA. A network meta‐analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression. World Psychiatry. 2020;19(1):92–107. DOI: 10.1002/wps.20701

251. Furukawa TA, Shinohara K, Sahker E, Karyotaki E, Miguel C, Ciharova M et al. Initial treatment choices to achieve sustained response in major depression: a systematic review and network meta‐analysis. World Psychiatry. 2021;20(3):387–96. DOI: 10.1002/wps.20906

252. Guidi J, Fava GA. Sequential Combination of Pharmacotherapy and Psychotherapy in Major Depressive Disorder: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2021;78(3):261–9. DOI: 10.1001/jamapsychiatry.2020.3650

253. Noetel M, Sanders T, Gallardo-Gómez D, Taylor P, Del Pozo Cruz B, Van Den Hoek D et al. Effect of exercise for depression: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2024;384:e075847. DOI: 10.1136/bmj-2023-075847

254. Tao Y, Lu J, Lv J, Zhang L. Effects of high-intensity interval training on depressive symptoms: A systematic review and meta-analysis. Journal of Psychosomatic Research. 2024;180:111652. DOI: 10.1016/j.jpsychores.2024.111652

255. Schuch F, Vancampfort D, Firth J, Rosenbaum S, Ward P, Reichert T et al. Physical activity and sedentary behavior in people with major depressive disorder: A systematic review and meta-analysis. Journal of Affective Disorders. 2017;210:139–50. DOI: 10.1016/j.jad.2016.10.050

256. Schuch FB, Vancampfort D, Richards J, Rosenbaum S, Ward PB, Stubbs B. Exercise as a treatment for depression: A meta-analysis adjusting for publication bias. Journal of Psychiatric Research. 2016;77:42–51. DOI: 10.1016/j.jpsychires.2016.02.023

257. Schuch FB, Vancampfort D, Rosenbaum S, Richards J, Ward PB, Stubbs B. Exercise improves physical and psychological quality of life in people with depression: A meta-analysis including the evaluation of control group response. Psychiatry Research. 2016;241:47–54. DOI: 10.1016/j.psychres.2016.04.054

258. Haddad M, Walters P, Phillips R, Tsakok J, Williams P, Mann A et al. Detecting Depression in Patients with Coronary Heart Disease: a Diagnostic Evaluation of the PHQ-9 and HADS-D in Primary Care, Findings From the UPBEAT-UK Study. PLoS ONE. 2013;8(10):e78493. DOI: 10.1371/journal.pone.0078493

259. Yuan J, Ding R, Wang L, Sheng L, Li J, Hu D. Screening for depression in acute coronary syndrome patients: A comparison of Patient Health Questionnaire-9 versus Hospital Anxiety and Depression Scale-Depression. Journal of Psychosomatic Research. 2019;121:24–8. DOI: 10.1016/j.jpsychores.2019.03.018

260. Frasure-Smith N, Lespérance F. Depression and Anxiety as Predictors of 2-Year Cardiac Events in Patients With Stable Coronary Artery Disease. Archives of General Psychiatry. 2008;65(1):62–71. DOI: 10.1001/archgenpsychiatry.2007.4

261. Harshfield EL, Pennells L, Schwartz JE, Willeit P, Kaptoge S, Bell S et al. Association Between Depressive Symptoms and Incident Cardiovascular Diseases. JAMA. 2020;324(23):2396–405. DOI: 10.1001/jama.2020.23068

262. Lee SN, Yun J-S, Ko S-H, Ahn Y-B, Yoo K-D, Her S-H et al. Impacts of gender and lifestyle on the association between depressive symptoms and cardiovascular disease risk in the UK Biobank. Scientific Reports. 2023;13(1):10758. DOI: 10.1038/s41598-023-37221-x

263. Rajan S, McKee M, Rangarajan S, Bangdiwala S, Rosengren A, Gupta R et al. Association of Symptoms of Depression With Cardiovascular Disease and Mortality in Low-, Middle-, and High-Income Countries. JAMA Psychiatry. 2020;77(10):1052–63. DOI: 10.1001/jamapsychiatry.2020.1351

264. Chen X, Liu Z, Yang Y, Chen G, Wan Q, Qin G et al. Depression Status, Lifestyle, and Metabolic Factors With Subsequent Risk for Major Cardiovascular Events: The China Cardiometabolic Disease and Cancer Cohort (4C) Study. Frontiers in Cardiovascular Medicine. 2022;9:865063. DOI: 10.3389/fcvm.2022.865063

265. Wei J, Hou R, Zhang X, Xu H, Xie L, Chandrasekar EK et al. The association of late-life depression with all-cause and cardiovascular mortality among community-dwelling older adults: systematic review and meta-analysis. British Journal of Psychiatry. 2019;215(2):449–55. DOI: 10.1192/bjp.2019.74

266. Krittanawong C, Maitra NS, Qadeer YK, Wang Z, Fogg S, Storch EA et al. Association of Depression and Cardiovascular Disease. The American Journal of Medicine. 2023;136(9):881–95. DOI: 10.1016/j.amjmed.2023.04.036

267. Katzmann J, Mahfoud F, Böhm M, Schulz M, Laufs U. Association of medication adherence and depression with the control of low-density lipoprotein cholesterol and blood pressure in patients at high cardiovascular risk. Patient Preference and Adherence. 2018;13:9–19. DOI: 10.2147/PPA.S182765

268. Hamieh N, Kab S, Zins M, Blacher J, Meneton P, Empana J-P et al. Depressive symptoms and non-adherence to treatable cardiovascular risk factors’ medications in the CONSTANCES cohort. European Heart Journal - Cardiovascular Pharmacotherapy. 2021;7(4):280–6. DOI: 10.1093/ehjcvp/pvaa124

269. Colquhoun D, Malawaraarachchi N, Ferreira-Jardim A. Poor adherence to anticoagulant therapy: a call to screen and treat depression in patients with atrial fibrillation. Heart, Lung and Circulation. 2015;24:S389–90. DOI: 10.1016/j.hlc.2015.06.646

270. Crawshaw J, Auyeung V, Norton S, Weinman J. Identifying psychosocial predictors of medication non-adherence following acute coronary syndrome: A systematic review and meta-analysis. Journal of Psychosomatic Research. 2016;90:10–32. DOI: 10.1016/j.jpsychores.2016.09.003

271. Grenard JL, Munjas BA, Adams JL, Suttorp M, Maglione M, McGlynn EA et al. Depression and Medication Adherence in the Treatment of Chronic Diseases in the United States: A Meta-Analysis. Journal of General Internal Medicine. 2011;26(10):1175–82. DOI: 10.1007/s11606-011-1704-y

272. Gonzalez JS, Peyrot M, McCarl LA, Collins EM, Serpa L, Mimiaga MJ et al. Depression and Diabetes Treatment Nonadherence: A Meta-Analysis. Diabetes Care. 2008;31(12):2398–403. DOI: 10.2337/dc08-1341

273. Poletti V, Pagnini F, Banfi P, Volpato E. The Role of Depression on Treatment Adherence in Patients with Heart Failure – a Systematic Review of the Literature. Current Cardiology Reports. 2022;24(12):1995–2008. DOI: 10.1007/s11886-022-01815-0

274. VA/DoD Clinical Practice Guideline. (2022). The Management of Major Depressive Disorder. Washington, DC: U.S. Government Printing Office. 2022. 160p. Av. at: https://www.healthquality.va.gov/guidelines/MH/mdd/VADODMDDCPGFinal508.pdf

275. Lewis G, Marston L, Duffy L, Freemantle N, Gilbody S, Hunter R et al. Maintenance or Discontinuation of Antidepressants in Primary Care. New England Journal of Medicine. 2021;385(14):1257–67. DOI: 10.1056/NEJMoa2106356

276. Kato M, Hori H, Inoue T, Iga J, Iwata M, Inagaki T et al. Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis. Molecular Psychiatry. 2021;26(1):118–33. DOI: 10.1038/s41380-020-0843-0

277. Zhou D, Lv Z, Shi L, Zhou X, Lin Q, Chen X et al. Effects of antidepressant medicines on preventing relapse of unipolar depression: a pooled analysis of parametric survival curves. Psychological Medicine. 2022;52(1):48–56. DOI: 10.1017/S0033291720001610

278. Liu X, Momen NC, Molenaar N, Rommel A-S, Bergink V, Munk-Olsen T. Discontinuation of antidepressants: Is there a minimum time on treatment that will reduce relapse risk? Journal of Affective Disorders. 2021;290:254–60. DOI: 10.1016/j.jad.2021.04.045

279. Safren SA, Gonzalez JS, Wexler DJ, Psaros C, Delahanty LM, Blashill AJ et al. A Randomized Controlled Trial of Cognitive Behavioral Therapy for Adherence and Depression (CBT-AD) in Patients With Uncontrolled Type 2 Diabetes. Diabetes Care. 2014;37(3):625–33. DOI: 10.2337/dc13-0816

280. Kronish IM, Rieckmann N, Burg MM, Edmondson D, Schwartz JE, Davidson KW. The effect of enhanced depression care on adherence to risk-reducing behaviors after acute coronary syndromes: Findings from the COPES trial. American Heart Journal. 2012;164(4):524–9. DOI: 10.1016/j.ahj.2012.07.024

281. Bauer LK, Caro MA, Beach SR, Mastromauro CA, Lenihan E, Januzzi JL et al. Effects of Depression and Anxiety Improvement on Adherence to Medication and Health Behaviors in Recently Hospitalized Cardiac Patients. The American Journal of Cardiology. 2012;109(9):1266–71. DOI: 10.1016/j.amjcard.2011.12.017

282. Rohde C, Knudsen JS, Schmitz N, Østergaard SD, Thomsen RW. The impact of hospital-diagnosed depression or use of antidepressants on treatment initiation, adherence and HbA1c/LDL target achievement in newly diagnosed type 2 diabetes. Diabetologia. 2021;64(2):361–74. DOI: 10.1007/s00125-020-05303-4

283. Kariis HM, Kasela S, Jürgenson T, Saar A, Lass J, Krebs K et al. The role of depression and antidepressant treatment in antihypertensive medication adherence and persistence: Utilising electronic health record data. Journal of Psychiatric Research. 2023;168:269–78. DOI: 10.1016/j.jpsychires.2023.10.018

284. Leung LB, Chu K, Rose D, Stockdale S, Post EP, Wells KB et al. Electronic Population-Based Depression Detection and Management Through Universal Screening in the Veterans Health Administration. JAMA Network Open. 2022;5(3):e221875. DOI: 10.1001/jamanetworkopen.2022.1875

285. Brinck-Claussen UØ, Curth NK, Christensen KS, Davidsen AS, Mikkelsen JH, Lau ME et al. Improving the precision of depression diagnosis in general practice: a cluster-randomized trial. BMC Family Practice. 2021;22(1):88. DOI: 10.1186/s12875-021-01432-w

286. Löwe B, Scherer M, Braunschneider L-E, Marx G, Eisele M, Mallon T et al. Clinical effectiveness of patient-targeted feedback following depression screening in general practice (GET.FEEDBACK.GP): an investigator-initiated, prospective, multicentre, three-arm, observerblinded, randomised controlled trial in Germany. The Lancet Psychiatry. 2024;11(4):262–73. DOI: 10.1016/S2215-0366(24)00035-X

287. Wang J, Wu X, Lai W, Long E, Zhang X, Li W et al. Prevalence of depression and depressive symptoms among outpatients: a systematic review and meta-analysis. BMJ Open. 2017;7(8):e017173. DOI: 10.1136/bmjopen-2017-017173

288. Moradi Y, Albatineh AN, Mahmoodi H, Gheshlagh RG. The relationship between depression and risk of metabolic syndrome: a meta‐analysis of observational studies. Clinical Diabetes and Endocrinology. 2021;7(1):4. DOI: 10.1186/s40842-021-00117-8

289. Amare AT, Schubert KO, Klingler-Hoffmann M, Cohen-Woods S, Baune BT. The genetic overlap between mood disorders and cardiometabolic diseases: a systematic review of genome wide and candidate gene studies. Translational Psychiatry. 2017;7(1):e1007. DOI: 10.1038/tp.2016.261

290. Lapa ME, Swabe GM, Magnani JW. Association of Depression and Adherence to Oral Anticoagulation in Patients With Atrial Fibrillation. Journal of the American Heart Association. 2023;12(22):e031281. DOI: 10.1161/JAHA.123.031281

291. Gathright EC, Dolansky MA, Gunstad J, Redle JD, Josephson RA, Moore SM et al. The impact of medication nonadherence on the relationship between mortality risk and depression in heart failure. Health Psychology. 2017;36(9):839–47. DOI: 10.1037/hea0000529

292. Herring MP. Effect of Exercise Training on Depressive Symptoms Among Patients With a Chronic Illness: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Archives of Internal Medicine. 2012;172(2):101–11. DOI: 10.1001/archinternmed.2011.696

293. Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. The Lancet. 2018;391(10128):1357–66. DOI: 10.1016/S0140-6736(17)32802-7

294. Strawbridge R, Carter B, Marwood L, Bandelow B, Tsapekos D, Nikolova VL et al. Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis. British Journal of Psychiatry. 2019;214(1):42–51. DOI: 10.1192/bjp.2018.233

295. Davies P, Ijaz S, Williams CJ, Kessler D, Lewis G, Wiles N. Pharmacological interventions for treatment-resistant depression in adults. Cochrane Database of Systematic Reviews. 2019;12:CD010557. DOI: 10.1002/14651858.CD010557.pub2

296. Li C-T, Bai Y-M, Huang Y-L, Chen Y-S, Chen T-J, Cheng J-Y et al. Association between antidepressant resistance in unipolar depression and subsequent bipolar disorder: cohort study. British Journal of Psychiatry. 2012;200(1):45–51. DOI: 10.1192/bjp. bp.110.086983

297. VA/DOD Clinical Practice Guideline for the Management of Posttraumatic Stress Disorder And Acute Stress Disorder. Version 4.0. 2023. 167p. Av. at: https://www.healthquality.va.gov/guidelines/MH/ptsd/VA-DoD-CPG-PTSD-Full-CPG-Edited-11162024.pdf

298. Phelps AJ, Lethbridge R, Brennan S, Bryant RA, Burns P, Cooper JA et al. Australian guidelines for the prevention and treatment of posttraumatic stress disorder: Updates in the third edition. Australian & New Zealand Journal of Psychiatry. 2022;56(3):230–47. DOI: 10.1177/00048674211041917

299. American Psychological Association. Clinical Practice Guideline for the Treatment of Posttraumatic Stress Disorder (PTSD) in Adults. 2017. 119p. Av. at: https://www.apa.org/ptsd-guideline/ptsd.pdf

300. Coventry PA, Meader N, Melton H, Temple M, Dale H, Wright K et al. Psychological and pharmacological interventions for posttraumatic stress disorder and comorbid mental health problems following complex traumatic events: Systematic review and component network meta-analysis. PLOS Medicine. 2020;17(8):e1003262. DOI: 10.1371/journal.pmed.1003262

301. Lewis C, Roberts NP, Andrew M, Starling E, Bisson JI. Psychological therapies for posttraumatic stress disorder in adults: systematic review and meta-analysis. European Journal of Psychotraumatology. 2020;11(1):1729633. DOI: 10.1080/20008198.2020.1729633

302. Merz J, Schwarzer G, Gerger H. Comparative Efficacy and Acceptability of Pharmacological, Psychotherapeutic, and Combination Treatments in Adults With Posttraumatic Stress Disorder: A Network Metaanalysis. JAMA Psychiatry. 2019;76(9):904–13. DOI: 10.1001/jamapsychiatry.2019.0951

303. Lee DJ, Schnitzlein CW, Wolf JP, Vythilingam M, Rasmusson AM, Hoge CW. Psychotherapy versus pharmacotherapy for posttraumatic stress disorder: systemic review and meta-analyses to determine firstline treatments. Depression and Anxiety. 2016;33(9):792–806. DOI: 10.1002/da.22511

304. Beristianos MH, Yaffe K, Cohen B, Byers AL. PTSD and Risk of Incident Cardiovascular Disease in Aging Veterans. The American Journal of Geriatric Psychiatry. 2016;24(3):192–200. DOI: 10.1016/j.jagp.2014.12.003

305. Roer GE, Lien L, Bolstad I, Aaseth JO, Abebe DS. The impact of PTSD on risk of cardiometabolic diseases: a national patient cohort study in Norway. BMC Psychiatry. 2023;23(1):349. DOI: 10.1186/s12888-023-04866-x

306. Gradus JL, Farkas DK, Svensson E, Ehrenstein V, Lash TL, Milstein A et al. Associations between stress disorders and cardiovascular disease events in the Danish population. BMJ Open. 2015;5(12):e009334. DOI: 10.1136/bmjopen-2015-009334

307. Rauch SAM, Kim HM, Powell C, Tuerk PW, Simon NM, Acierno R et al. Efficacy of Prolonged Exposure Therapy, Sertraline Hydrochloride, and Their Combination Among Combat Veterans With Posttraumatic Stress Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2019;76(2):117–26. DOI: 10.1001/jamapsychiatry.2018.3412

308. Zoellner LA, Roy-Byrne PP, Mavissakalian M, Feeny NC. Doubly Randomized Preference Trial of Prolonged Exposure Versus Sertraline for Treatment of PTSD. American Journal of Psychiatry. 2019;176(4):287–96. DOI: 10.1176/appi.ajp.2018.17090995

309. Williams T, Phillips NJ, Stein DJ, Ipser JC. Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database of Systematic Reviews. 2022;3(3):CD002795. DOI: 10.1002/14651858.CD002795.pub3

310. Cipriani A, Williams T, Nikolakopoulou A, Salanti G, Chaimani A, Ipser J et al. Comparative efficacy and acceptability of pharmacological treatments for posttraumatic stress disorder in adults: a network meta-analysis. Psychological Medicine. 2018;48(12):1975–84. DOI: 10.1017/S003329171700349X

311. De Moraes Costa G, Zanatta FB, Ziegelmann PK, Soares Barros AJ, Mello CF. Pharmacological treatments for adults with posttraumatic stress disorder: A network meta-analysis of comparative efficacy and acceptability. Journal of Psychiatric Research. 2020;130:412–20. DOI: 10.1016/j.jpsychires.2020.07.046

312. LeardMann CA, Kelton ML, Smith B, Littman AJ, Boyko EJ, Wells TS et al. Prospectively Assessed Posttraumatic Stress Disorder and Associated Physical Activity. Public Health Reports®. 2011;126(3):371–83. DOI: 10.1177/003335491112600311

313. Jadhakhan F, Lambert N, Middlebrook N, Evans DW, Falla D. Is exercise/physical activity effective at reducing symptoms of posttraumatic stress disorder in adults – A systematic review. Frontiers in Psychology. 2022;13:943479. DOI: 10.3389/fpsyg.2022.943479

314. Björkman F, Ekblom Ö. Physical Exercise as Treatment for PTSD: A Systematic Review and Meta-Analysis. Military Medicine. 2022;187(9–10):e1103–13. DOI: 10.1093/milmed/usab497

315. Guina J, Rossetter SR, DeRHODES BJ, Nahhas RW, Welton RS. Benzodiazepines for PTSD: A Systematic Review and Meta-Analysis. Journal of Psychiatric Practice. 2015;21(4):281–303. DOI: 10.1097/PRA.0000000000000091

316. Gates MA, Holowka DW, Vasterling JJ, Keane TM, Marx BP, Rosen RC. Posttraumatic stress disorder in veterans and military personnel: Epidemiology, screening, and case recognition. Psychological Services. 2012;9(4):361–82. DOI: 10.1037/a0027649

317. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jönsson B et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. European Neuropsychopharmacology. 2011;21(9):655–79. DOI: 10.1016/j.euroneuro.2011.07.018

318. Huo N, Vemuri P, Graff-Radford J, Syrjanen J, Machulda M, Knopman DS et al. Sex Differences in the Association Between Midlife Cardiovascular Conditions or Risk Factors With Midlife Cognitive Decline. Neurology. 2022;98(6):e623–32. DOI: 10.1212/WNL.0000000000013174

319. Liang X, Huang Y, Han X. Associations between coronary heart disease and risk of cognitive impairment: A meta‐analysis. Brain and Behavior. 2021;11(5):e02108. DOI: 10.1002/brb3.2108

320. Adelborg K, Horváth‐Puhó E, Ording A, Pedersen L, Sørensen HT, Henderson VW. Heart failure and risk of dementia: a Danish nationwide population‐based cohort study. European Journal of Heart Failure. 2017;19(2):253–60. DOI: 10.1002/ejhf.631

321. Mulligan MD, Murphy R, Reddin C, Judge C, Ferguson J, Alvarez-Iglesias A et al. Population attributable fraction of hypertension for dementia: global, regional, and national estimates for 186 countries. eClinicalMedicine. 2023;60:102012. DOI: 10.1016/j.eclinm.2023.102012

322. Zuin M, Roncon L, Passaro A, Bosi C, Cervellati C, Zuliani G. Risk of dementia in patients with atrial fibrillation: Short versus long follow‐up. A systematic review and meta‐analysis. International Journal of Geriatric Psychiatry. 2021;36(10):1488–500. DOI: 10.1002/gps.5582

323. Kuźma E, Lourida I, Moore SF, Levine DA, Ukoumunne OC, Llewellyn DJ. Stroke and dementia risk: A systematic review and meta‐analysis. Alzheimer’s & Dementia. 2018;14(11):1416–26. DOI: 10.1016/j.jalz.2018.06.3061

324. Lee W, Kang S, Kim S, Lee S, Myung W, Jheon K et al. Impact of dementia and drug compliance on patients with acute myocardial infarction. Clinical Cardiology. 2023;46(10):1253–9. DOI: 10.1002/clc.24091

325. El-Saifi N, Moyle W, Jones C, Tuffaha H. Medication Adherence in Older Patients With Dementia: A Systematic Literature Review. Journal of Pharmacy Practice. 2018;31(3):322–34. DOI: 10.1177/0897190017710524

326. Cho MH, Shin DW, Chang S-A, Lee JE, Jeong S-M, Kim SH et al. Association between cognitive impairment and poor antihypertensive medication adherence in elderly hypertensive patients without dementia. Scientific Reports. 2018;8(1):11688. DOI: 10.1038/s41598-018-29974-7

327. Dolansky MA, Hawkins MAW, Schaefer JT, Sattar A, Gunstad J, Redle JD et al. Association Between Poorer Cognitive Function and Reduced Objectively Monitored Medication Adherence in Patients With Heart Failure. Circulation: Heart Failure. 2016;9(12):e002475. DOI: 10.1161/CIRCHEARTFAILURE.116.002475

328. Patnode CD, Perdue LA, Rossom RC, Rushkin MC, Redmond N, Thomas RG et al. Screening for Cognitive Impairment in Older Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2020;323(8):764–85. DOI: 10.1001/jama.2019.22258

329. Ngandu T, Lehtisalo J, Solomon A, Levälahti E, Ahtiluoto S, Antikainen R et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. The Lancet. 2015;385(9984):2255–63. DOI: 10.1016/S0140-6736(15)60461-5

330. Na R, Yang J, Yeom Y, Kim YJ, Byun S, Kim K et al. A Systematic Review and Meta-Analysis of Nonpharmacological Interventions for Moderate to Severe Dementia. Psychiatry Investigation. 2019;16(5):325–35. DOI: 10.30773/pi.2019.02.11.2

331. Zhou S, Chen S, Liu X, Zhang Y, Zhao M, Li W. Physical Activity Improves Cognition and Activities of Daily Living in Adults with Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. International Journal of Environmental Research and Public Health. 2022;19(3):1216. DOI: 10.3390/ijerph19031216

332. Ornish D, Madison C, Kivipelto M, Kemp C, McCulloch CE, Galasko D et al. Effects of intensive lifestyle changes on the progression of mild cognitive impairment or early dementia due to Alzheimer’s disease: a randomized, controlled clinical trial. Alzheimer’s Research & Therapy. 2024;16(1):122. DOI: 10.1186/s13195-024-01482-z

333. Woods B, Rai HK, Elliott E, Aguirre E, Orrell M, Spector A. Cognitive stimulation to improve cognitive functioning in people with dementia. Cochrane Database of Systematic Reviews. 2023;1:CD005562. DOI: 10.1002/14651858.CD005562.pub3

334. Kudlicka A, Martyr A, Bahar-Fuchs A, Sabates J, Woods B, Clare L. Cognitive rehabilitation for people with mild to moderate dementia. Cochrane Database of Systematic Reviews. 2023;6:CD013388. DOI: 10.1002/14651858.CD013388.pub2

335. Bahar-Fuchs A, Martyr A, Goh AM, Sabates J, Clare L. Cognitive training for people with mild to moderate dementia. Cochrane Database of Systematic Reviews. 2019;3:CD013069. DOI: 10.1002/14651858.CD013069.pub2

336. Saragih ID, Tonapa SI, Saragih IS, Lee BO. Effects of cognitive stimulation therapy for people with dementia: A systematic review and meta-analysis of randomized controlled studies. International Journal of Nursing Studies. 2022;128:104181. DOI: 10.1016/j.ijnurstu.2022.104181

337. Kishi T, Matsunaga S, Oya K, Nomura I, Ikuta T, Iwata N. Memantine for Alzheimer’s Disease: An Updated Systematic Review and Meta-analysis. Journal of Alzheimer’s Disease. 2017;60(2):401–25. DOI: 10.3233/JAD-170424

338. McShane R, Westby MJ, Roberts E, Minakaran N, Schneider L, Farrimond LE et al. Memantine for dementia. Cochrane Database of Systematic Reviews. 2019;3:CD003154. DOI: 10.1002/14651858.CD003154.pub6

339. Birks JS, Grimley Evans J. Rivastigmine for Alzheimer’s disease. Cochrane Database of Systematic Reviews. 2015;4:CD001191. DOI: 10.1002/14651858.CD001191.pub3

340. Rojas-Fernandez CH. Little evidence that cholinesterase inhibitors prevent progression of mild cognitive impairment to dementia, but they are associated with adverse effects. Evidence Based Mental Health. 2013;16(2):39. DOI: 10.1136/eb-2012-101087

341. Vaci N, Koychev I, Kim CH, Kormilitzin A, Liu Q, Lucas C et al. Real-world effectiveness, its predictors and onset of action of cholinesterase inhibitors and memantine in dementia: retrospective health record study. The British Journal of Psychiatry. 2021;218(5):261–7. DOI: 10.1192/bjp.2020.136

342. Гаврилова С.И., Колыхалов И.В., Михайлова Н.М., Пономарева Е.В., Федорова Я.Б., Медведев В.Э. и др. Многоцентровое открытое сравнительное рандомизированное исследование эффективности и безопасности применения препарата Акатинол Мемантин, 20 мг (однократный прием) в сравнении с препаратом Акатинол Мемантин, 10 мг (двукратный прием) у пациентов с сосудистой деменцией. Журнал неврологии и психиатрии им. С.С. Корсакова. 2024;124(2):69–77. DOI: 10.17116/jnevro202412402169

343. Parish S, Mafham M, Offer A, Barton J, Wallendszus K, Stevens W et al. Effects of aspirin on dementia and cognitive function in diabetic patients: the ASCEND trial. European Heart Journal. 2022;43(21):2010–9. DOI: 10.1093/eurheartj/ehac179

344. Tao T, Feng G, Fang Y. Association between aspirin use and risk of dementia: a systematic review and meta-analysis. European Geriatric Medicine. 2023;15(1):3–18. DOI: 10.1007/s41999-023-00877-9

345. McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane Database of Systematic Reviews. 2016;1:CD003160. DOI: 10.1002/14651858.CD003160.pub3

346. Davis KAS, Bishara D, Perera G, Molokhia M, Rajendran L, Stewart RJ. Benefits and Harms of Statins in People with Dementia: A Systematic Review and Meta‐Analysis. Journal of the American Geriatrics Society. 2020;68(3):650–8. DOI: 10.1111/jgs.16342

347. Olmastroni E, Molari G, De Beni N, Colpani O, Galimberti F, Gazzotti M et al. Statin use and risk of dementia or Alzheimer’s disease: a systematic review and meta-analysis of observational studies. European Journal of Preventive Cardiology. 2022;29(5):804–14. DOI: 10.1093/eurjpc/zwab208

348. Zhou Z, Ryan J, Ernst ME, Zoungas S, Tonkin AM, Woods RL et al. Effect of Statin Therapy on Cognitive Decline and Incident Dementia in Older Adults. Journal of the American College of Cardiology. 2021;77(25):3145–56. DOI: 10.1016/j.jacc.2021.04.075

349. Jack CR, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A et al. Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup. Alzheimer’s & Dementia. 2024;20(8):5143–69. DOI: 10.1002/alz.13859

350. Meijer A, Conradi HJ, Bos EH, Anselmino M, Carney RM, Denollet J et al. Adjusted prognostic association of depression following myocardial infarction with mortality and cardiovascular events: individual patient data meta-analysis. British Journal of Psychiatry. 2013;203(2):90–102. DOI: 10.1192/bjp.bp.112.111195

351. Doyle F, McGee H, Conroy R, Conradi HJ, Meijer A, Steeds R et al. Systematic Review and Individual Patient Data Meta-Analysis of Sex Differences in Depression and Prognosis in Persons With Myocardial Infarction: A MINDMAPS Study. Psychosomatic Medicine. 2015;77(4):419–28. DOI: 10.1097/PSY.0000000000000174

352. Roest AM, Martens EJ, Denollet J, De Jonge P. Prognostic Association of Anxiety Post Myocardial Infarction With Mortality and New Cardiac Events: A Meta-Analysis. Psychosomatic Medicine. 2010;72(6):563–9. DOI: 10.1097/PSY.0b013e3181dbff97

353. Kronish IM, Edmondson D, Moise N, Chang BP, Wei Y, Veneros DL et al. Posttraumatic stress disorder in patients who rule out versus rule in for acute coronary syndrome. General Hospital Psychiatry. 2018;53:101–7. DOI: 10.1016/j.genhosppsych.2018.02.007

354. Edmondson D, Richardson S, Falzon L, Davidson KW, Mills MA, Neria Y. Posttraumatic Stress Disorder Prevalence and Risk of Recurrence in Acute Coronary Syndrome Patients: A Meta-analytic Review. PLoS ONE. 2012;7(6):e38915. DOI: 10.1371/journal.pone.0038915

355. Dong Z, Yang Q, Chen H. Estimating the prevalence of depression in people with acute coronary syndromes: A systematic review and meta-analysis. Medicine. 2024;103(17):e37906. DOI: 10.1097/MD.0000000000037906

356. Gustad LT, Laugsand LE, Janszky I, Dalen H, Bjerkeset O. Symptoms of anxiety and depression and risk of acute myocardial infarction: the HUNT 2 study. European Heart Journal. 2014;35(21):1394–403. DOI: 10.1093/eurheartj/eht387

357. Rosengren A, Hawken S, Ôunpuu S, Sliwa K, Zubaid M, Almahmeed WA et al. Association of psychosocial risk factors with risk of acute myocardial infarction in 11 119 cases and 13 648 controls from 52 countries (the INTERHEART study): case-control study. The Lancet. 2004;364(9438):953–62. DOI: 10.1016/S0140-6736(04)17019-0

358. Scherrer JF, Chrusciel T, Zeringue A, Garfield LD, Hauptman PJ, Lustman PJ et al. Anxiety disorders increase risk for incident myocardial infarction in depressed and nondepressed Veterans Administration patients. American Heart Journal. 2010;159(5):772–9. DOI: 10.1016/j.ahj.2010.02.033

359. Chen Y-H, Tsai S-Y, Lee H-C, Lin H-C. Increased Risk of Acute Myocardial Infarction for Patients With Panic Disorder: A Nationwide Population-Based Study. Psychosomatic Medicine. 2009;71(7):798–804. DOI: 10.1097/PSY.0b013e3181ad55e3

360. Flygare O, Boberg J, Rück C, Hofmann R, Leosdottir M, MataixCols D et al. Association of anxiety or depression with risk of recurrent cardiovascular events and death after myocardial infarction: A nationwide registry study. International Journal of Cardiology. 2023;381:120–7. DOI: 10.1016/j.ijcard.2023.04.023

361. Myers V, Gerber Y, Benyamini Y, Goldbourt U, Drory Y. Post-myocardial infarction depression: Increased hospital admissions and reduced adoption of secondary prevention measures – A longitudinal study. Journal of Psychosomatic Research. 2012;72(1):5–10. DOI: 10.1016/j.jpsychores.2011.09.009

362. Kim J-M, Stewart R, Bae K-Y, Kang H-J, Kim S-W, Shin I-S et al. Effects of depression comorbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychological Medicine. 2015;45(8):1641–52. DOI: 10.1017/S003329171400275X

363. Kim J-M, Stewart R, Lee Y-S, Lee H-J, Kim MC, Kim J-W et al. Effect of Escitalopram vs Placebo Treatment for Depression on Longterm Cardiac Outcomes in Patients With Acute Coronary Syndrome: A Randomized Clinical Trial. JAMA. 2018;320(4):350–8. DOI: 10.1001/jama.2018.9422

364. Glassman AH, O’Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT Jr et al. Sertraline Treatment of Major Depression in Patients With Acute MI or Unstable Angina. JAMA. 2002;288(6):701–9. DOI: 10.1001/jama.288.6.701

365. Van Melle JP, De Jonge P, Honig A, Schene AH, Kuyper AMG, Crijns HJGM et al. Effects of antidepressant treatment following myocardial infarction. British Journal of Psychiatry. 2007;190(6):460–6. DOI: 10.1192/bjp.bp.106.028647

366. Berkman LF, Blumenthal J, Burg M, Carney RM, Catellier D, Cowan MJ et al. Effects of Treating Depression and Low Perceived Social Support on Clinical Events After Myocardial Infarction: The Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA. 2003;289(23):3106–16. DOI: 10.1001/jama.289.23.3106

367. Abdullah A, Eigbire G, Salama A, Wahab A, Awadalla M, Hoefen R et al. Impact of delirium on patients hospitalized for myocardial infarction: A propensity score analysis of the National Inpatient Sample. Clinical Cardiology. 2018;41(7):910–5. DOI: 10.1002/clc.22972

368. Jäckel M, Zotzmann V, Wengenmayer T, Duerschmied D, Biever PM, Spieler D et al. Incidence and predictors of delirium on the intensive care unit after acute myocardial infarction, insight from a retrospective registry. Catheterization and Cardiovascular Interventions. 2021;98(6):1072–81. DOI: 10.1002/ccd.29275

369. Patil S, Gonuguntala K, Rojulpote C, Kumar M, Corradi JP, Chen K. Delirium is an important predictor of mortality in elderly patients with ST-elevation myocardial infarction: insight from National Inpatient Sample database. Coronary Artery Disease. 2020;31(8):665–70. DOI: 10.1097/MCA.0000000000000978

370. Kang H-J, Stewart R, Bae K-Y, Kim S-W, Shin I-S, Hong YJ et al. Effects of depression screening on psychiatric outcomes in patients with acute coronary syndrome: Findings from the K-DEPACS and EsDEPACS studies. International Journal of Cardiology. 2015;190:114–21. DOI: 10.1016/j.ijcard.2015.04.164

371. Kronish IM, Moise N, Cheung YK, Clarke GN, Dolor RJ, Duer-Hefele J et al. Effect of Depression Screening After Acute Coronary Syndromes on Quality of Life: The CODIACS-QoL Randomized Clinical Trial. JAMA Internal Medicine. 2020;180(1):45–53. DOI: 10.1001/jamainternmed.2019.4518

372. Ladapo JA, Davidson KW, Moise N, Chen A, Clarke GN, Dolor RJ et al. Economic outcomes of depression screening after acute coronary syndromes: The CODIACS-QoL randomized clinical trial. General Hospital Psychiatry. 2021;71:47–54. DOI: 10.1016/j.genhosppsych.2021.04.001

373. Sweda R, Siontis GCM, Nikolakopoulou A, Windecker S, Pilgrim T. Antidepressant treatment in patients following acute coronary syndromes: a systematic review and Bayesian meta‐analysis. ESC Heart Failure. 2020;7(6):3610–20. DOI: 10.1002/ehf2.12861

374. Li J, Ji F, Song J, Gao X, Jiang D, Chen G et al. Anxiety and clinical outcomes of patients with acute coronary syndrome: a metaanalysis. BMJ Open. 2020;10(7):e034135. DOI: 10.1136/bmjopen-2019-034135

375. Honkola J, Hookana E, Malinen S, Kaikkonen KS, Junttila MJ, Isohanni M et al. Psychotropic medications and the risk of sudden cardiac death during an acute coronary event. European Heart Journal. 2012;33(6):745–51. DOI: 10.1093/eurheartj/ehr368

376. Ben-Shoshan J, Segman-Rosenstveig Y, Arbel Y, Chorin E, Barkagan M, Rozenbaum Z et al. Comparison of Triggering and Nontriggering Factors in ST-Segment Elevation Myocardial Infarction and Extent of Coronary Arterial Narrowing. The American Journal of Cardiology. 2016;117(8):1219–23. DOI: 10.1016/j.amjcard.2016.01.038

377. Tofler GH, Kopel E, Klempfner R, Eldar M, Buckley T, Goldenberg I. Triggers and Timing of Acute Coronary Syndromes. The American Journal of Cardiology. 2017;119(10):1560–5. DOI: 10.1016/j.amjcard.2017.02.022

378. Chan B, Buckley T, Tofler GH. Emotional Stress and Physical Exertion as Triggers of Acute Myocardial Infarction. The American Journal of Cardiology. 2023;203:285–7. DOI: 10.1016/j.amjcard.2023.07.085

379. Steptoe A, Strike PC, Perkins-Porras L, McEwan JR, Whitehead DL. Acute Depressed Mood as a Trigger of Acute Coronary Syndromes. Biological Psychiatry. 2006;60(8):837–42. DOI: 10.1016/j.biopsych.2006.03.041

380. Smyth A, O’Donnell M, Lamelas P, Teo K, Rangarajan S, Yusuf S. Physical Activity and Anger or Emotional Upset as Triggers of Acute Myocardial Infarction: The INTERHEART Study. Circulation. 2016;134(15):1059–67. DOI: 10.1161/CIRCULATIONAHA.116.023142

381. Lissåker CT, Norlund F, Wallert J, Held C, Olsson EM. Persistent emotional distress after a first-time myocardial infarction and its association to late cardiovascular and non-cardiovascular mortality. European Journal of Preventive Cardiology. 2019;26(14):1510–8. DOI: 10.1177/2047487319841475

382. Shang J, Dong J, Zhu S, Chen Q, Hua J. Trends in cognitive function before and after myocardial infarction: findings from the China Health and Retirement Longitudinal Study. Frontiers in Aging Neuroscience. 2024;16:1283997. DOI: 10.3389/fnagi.2024.1283997

383. Johansen MC, Ye W, Gross A, Gottesman RF, Han D, Whitney R et al. Association Between Acute Myocardial Infarction and Cognition. JAMA Neurology. 2023;80(7):723–31. DOI: 10.1001/jamaneurol.2023.1331

384. Park Y, Bateman BT, Kim DH, Hernandez-Diaz S, Patorno E, Glynn RJ et al. Use of haloperidol versus atypical antipsychotics and risk of inhospital death in patients with acute myocardial infarction: cohort study. BMJ. 2018;360:k1218. DOI: 10.1136/bmj.k1218

385. Белялов Ф.И. Депрессия, тревога и стресс у пациентов с ишемической болезнью сердца. Терапевтический архив. 2017;89(8):104–9. DOI: 10.17116/terarkh2017898104-109

386. Edmondson D, Kronish IM, Shaffer JA, Falzon L, Burg MM. Posttraumatic stress disorder and risk for coronary heart disease: A meta-analytic review. American Heart Journal. 2013;166(5):806–14. DOI: 10.1016/j.ahj.2013.07.031

387. Kemp AH, Brunoni AR, Nunes MA, Santos IS, Goulart AC, Ribeiro AL et al. The association between mood and anxiety disorders, and coronary heart disease in Brazil: a cross-sectional analysis on the Brazilian longitudinal study of adult health (ELSA-Brasil). Frontiers in Psychology. 2015;6:187. DOI: 10.3389/fpsyg.2015.00187

388. Gan Y, Gong Y, Tong X, Sun H, Cong Y, Dong X et al. Depression and the risk of coronary heart disease: a meta-analysis of prospective cohort studies. BMC Psychiatry. 2014;14(1):371. DOI: 10.1186/s12888-014-0371-z

389. Poole L, Steptoe A. Depressive symptoms predict incident chronic disease burden 10 years later: Findings from the English Longitudinal Study of Ageing (ELSA). Journal of Psychosomatic Research. 2018;113:30–6. DOI: 10.1016/j.jpsychores.2018.07.009

390. Herbst S, Pietrzak RH, Wagner J, White WB, Petry NM. Lifetime Major Depression is Associated With Coronary Heart Disease in Older Adults: Results From the National Epidemiologic Survey on Alcohol and Related Conditions. Psychosomatic Medicine. 2007;69(8):729–34. DOI: 10.1097/PSY.0b013e3181574977

391. Roest AM, Martens EJ, de Jonge P, Denollet J. Anxiety and Risk of Incident Coronary Heart Disease: A Meta-Analysis. Journal of the American College of Cardiology. 2010;56(1):38–46. DOI: 10.1016/j.jacc.2010.03.034

392. Emdin CA, Odutayo A, Wong CX, Tran J, Hsiao AJ, Hunn BHM. Meta-Analysis of Anxiety as a Risk Factor for Cardiovascular Disease. The American Journal of Cardiology. 2016;118(4):511–9. DOI: 10.1016/j.amjcard.2016.05.041

393. Tully PJ, Turnbull DA, Beltrame J, Horowitz J, Cosh S, Baumeister H et al. Panic disorder and incident coronary heart disease: a systematic review and meta-regression in 1 131 612 persons and 58 111 cardiac events. Psychological Medicine. 2015;45(14):2909–20. DOI: 10.1017/S0033291715000963

394. Derisi MM, Nasiri MJ, Aryan A, Moosavi Jarrahi A, Amiri P, Mohseny M. Prevalence of psychiatric disorders in patients with ischemic heart disease: A systematic review and meta-analysis. Journal of Research in Medical Sciences. 2022;27(1):12. DOI: 10.4103/jrms.JRMS_864_20

395. Boyle SH, Samad Z, Becker RC, Williams R, Kuhn C, Ortel TL et al. Depressive Symptoms and Mental Stress–Induced Myocardial Ischemia in Patients With Coronary Heart Disease. Psychosomatic Medicine. 2013;75(9):822–31. DOI: 10.1097/PSY.0b013e3182a893ae

396. Geovanini GR, Gowdak LHW, Pereira AC, Danzi-Soares NDJ, Dourado LOC, Poppi NT et al. OSA and Depression Are Common and Independently Associated With Refractory Angina in Patients With Coronary Artery Disease. Chest. 2014;146(1):73–80. DOI: 10.1378/chest.13-2885

397. Schopfer DW, Regan M, Heidenreich PA, Whooley MA. Depressive Symptoms, Cardiac Disease Severity, and Functional Status in Patients With Coronary Artery Disease (from the Heart and Soul Study). The American Journal of Cardiology. 2016;118(9):1287–92. DOI: 10.1016/j.amjcard.2016.07.062

398. Papasavvas T, Alhashemi M, Micklewright D. Association Between Depressive Symptoms and Exercise Capacity in Patients With Heart Disease: A Meta-analysis. Journal of Cardiopulmonary Rehabilitation and Prevention. 2017;37(4):239–49. DOI: 10.1097/HCR.0000000000000193

399. Lin S, Zhang H, Ma A. The association between depression and coronary artery calcification: A meta-analysis of observational studies. Journal of Affective Disorders. 2018;232:276–82. DOI: 10.1016/j.jad.2018.02.027

400. Tusa N, Kautiainen H, Elfving P, Sinikallio S, Mäntyselkä P. Depressive symptoms decrease health-related quality of life of patients with coronary artery disease and diabetes: a 12-month follow up study in primary care. Scandinavian Journal of Primary Health Care. 2023;41(3):276–86. DOI: 10.1080/02813432.2023.2233995

401. Нонка Т.Г., Лебедева Е.В., Репин А.Н. Клинические особенности ишемической болезни сердца и 5-летняя выживаемость больных после перенесенного инфаркта миокарда на фоне депрессивных расстройств. Терапевтический архив. 2024;96(1):17–21. DOI: 10.26442/00403660.2024.01.202560

402. Martens EJ, De Jonge P, Na B, Cohen BE, Lett H, Whooley MA. Scared to Death? Generalized Anxiety Disorder and Cardiovascular Events in Patients With Stable Coronary Heart Disease: The Heart and Soul Study. Archives of General Psychiatry. 2010;67(7):750–8. DOI: 10.1001/archgenpsychiatry.2010.74

403. Celano CM, Millstein RA, Bedoya CA, Healy BC, Roest AM, Huffman JC. Association between anxiety and mortality in patients with coronary artery disease: A meta-analysis. American Heart Journal. 2015;170(6):1105–15. DOI: 10.1016/j.ahj.2015.09.013

404. Tully PJ, Cosh SM, Baumeister H. The anxious heart in whose mind? A systematic review and meta-regression of factors associated with anxiety disorder diagnosis, treatment and morbidity risk in coronary heart disease. Journal of Psychosomatic Research. 2014;77(6):439–48. DOI: 10.1016/j.jpsychores.2014.10.001

405. Vaccarino V, Sullivan S, Hammadah M, Wilmot K, Al Mheid I, Ramadan R et al. Mental Stress–Induced-Myocardial Ischemia in Young Patients With Recent Myocardial Infarction: Sex Differences and Mechanisms. Circulation. 2018;137(8):794–805. DOI: 10.1161/CIRCULATIONAHA.117.030849

406. Wei J, Rooks C, Ramadan R, Shah AJ, Bremner JD, Quyyumi AA et al. Meta-Analysis of Mental Stress–Induced Myocardial Ischemia and Subsequent Cardiac Events in Patients With Coronary Artery Disease. The American Journal of Cardiology. 2014;114(2):187–92. DOI: 10.1016/j.amjcard.2014.04.022

407. Magán I, Jurado-Barba R, Casado L, Barnum H, Jeon A, Hernandez AV et al. Efficacy of psychological interventions on clinical outcomes of coronary artery disease: Systematic review and meta-analysis. Journal of Psychosomatic Research. 2022;153:110710. DOI: 10.1016/j.jpsychores.2021.110710

408. Doyle F, Freedland KE, Carney RM, De Jonge P, Dickens C, Pedersen SS et al. Hybrid Systematic Review and Network Meta-Analysis of Randomized Controlled Trials of Interventions for Depressive Symptoms in Patients With Coronary Artery Disease. Psychosomatic Medicine. 2021;83(5):423–31. DOI: 10.1097/PSY.0000000000000944

409. Dibben GO, Faulkner J, Oldridge N, Rees K, Thompson DR, Zwisler A-D et al. Exercise-based cardiac rehabilitation for coronary heart disease: a meta-analysis. European Heart Journal. 2023;44(6):452–69. DOI: 10.1093/eurheartj/ehac747

410. Blumenthal JA, Sherwood A, Babyak MA, Watkins LL, Smith PJ, Hoffman BM et al. Exercise and Pharmacological Treatment of Depressive Symptoms in Patients With Coronary Heart Disease. Journal of the American College of Cardiology. 2012;60(12):1053–63. DOI: 10.1016/j.jacc.2012.04.040

411. Wang L, Sun Y, Zhan J, Wu Z, Zhang P, Wen X et al. Effects of Exercise Therapy on Anxiety and Depression in Patients With Coronary Heart Disease: A Meta-Analysis of a Randomized Controlled Study. Frontiers in Cardiovascular Medicine. 2021;8:730155. DOI: 10.3389/fcvm.2021.730155

412. Greaves D, Psaltis PJ, Ross TJ, Davis D, Smith AE, Boord MS et al. Cognitive outcomes following coronary artery bypass grafting: A systematic review and meta-analysis of 91,829 patients. International Journal of Cardiology. 2019;289:43–9. DOI: 10.1016/j.ijcard.2019.04.065

413. Evered LA, Silbert BS, Scott DA, Maruff P, Ames D. Prevalence of Dementia 7.5 Years after Coronary Artery Bypass Graft Surgery. Anesthesiology. 2016;125(1):62–71. DOI: 10.1097/ALN.0000000000001143

414. Van Dijk MR, Utens EM, Dulfer K, Al-Qezweny MN, Van Geuns R-J, Daemen J et al. Depression and anxiety symptoms as predictors of mortality in PCI patients at 10 years of follow-up. European Journal of Preventive Cardiology. 2016;23(5):552–8. DOI: 10.1177/2047487315571889

415. Zhang WY, Nan N, Song XT, Tian JF, Yang XY. Impact of depression on clinical outcomes following percutaneous coronary intervention: a systematic review and meta-analysis. BMJ Open. 2019;9(8):e026445. DOI: 10.1136/bmjopen-2018-026445

416. Song X, Song J, Shao M, Gao X, Ji F, Tian H et al. Depression predicts the risk of adverse events after percutaneous coronary intervention: A meta-analysis. Journal of Affective Disorders. 2020;266:158–64. DOI: 10.1016/j.jad.2020.01.136

417. Geulayov G, Novikov I, Dankner D, Dankner R. Symptoms of depression and anxiety and 11-year all-cause mortality in men and women undergoing coronary artery bypass graft (CABG) surgery. Journal of Psychosomatic Research. 2018;105:106–14. DOI: 10.1016/j.jpsychores.2017.11.017

418. Stenman M, Holzmann MJ, Sartipy U. Association between preoperative depression and long-term survival following coronary artery bypass surgery – A systematic review and meta-analysis. International Journal of Cardiology. 2016;222:462–6. DOI: 10.1016/j.ijcard.2016.07.216

419. Stenman M, Holzmann MJ, Sartipy U. Relation of Major Depression to Survival After Coronary Artery Bypass Grafting. The American Journal of Cardiology. 2014;114(5):698–703. DOI: 10.1016/j.amjcard.2014.05.058

420. Akosile W, Colquhoun D, Young R, Lawford B, Voisey J. The association between posttraumatic stress disorder and coronary artery disease: a meta-analysis. Australasian Psychiatry. 2018;26(5):524–30. DOI: 10.1177/1039856218789779

421. Bouchard V, Robitaille A, Perreault S, Cyr M-C, Tardif J-C, Busseuil D et al. Psychological distress, social support, and use of outpatient care among adult men and women with coronary artery disease or other non-cardiovascular chronic disease. Journal of Psychosomatic Research. 2023;165:111131. DOI: 10.1016/j.jpsychores.2022.111131

422. Pedersen SS, Smith ORF, Vries JD, Appels A, Denollet J. Course of Anxiety Symptoms Over an 18-Month Period in Exhausted Patients Post Percutaneous Coronary Intervention. Psychosomatic Medicine. 2008;70(3):349–55. DOI: 10.1097/PSY.0b013e3181656540

423. Rawashdeh SI, Ibdah R, Kheirallah KA, Al-kasasbeh A, Raffee LA, Alrabadi N et al. Prevalence Estimates, Severity, and Risk Factors of Depressive Symptoms among Coronary Artery Disease Patients after Ten Days of Percutaneous Coronary Intervention. Clinical Practice & Epidemiology in Mental Health. 2021;17(1):103–13. DOI: 10.2174/1745017902117010103

424. Williams BA, Riangwiwat T, Voyce S, Blankenship JC. Burden and Predictors of Chest Pain-Related Health-Care Utilization Following Percutaneous Coronary Intervention. The American Journal of Cardiology. 2021;160:31–9. DOI: 10.1016/j.amjcard.2021.07.051

425. De Jager TAJ, Dulfer K, Radhoe S, Bergmann MJ, Daemen J, Van Domburg RT et al. Predictive value of depression and anxiety for long-term mortality: differences in outcome between acute coronary syndrome and stable angina pectoris. International Journal of Cardiology. 2018;250:43–8. DOI: 10.1016/j.ijcard.2017.10.005

426. Zhang H-Z, Shao B, Wang Q-Y, Wang Y-H, Cao Z-Z, Chen L-L et al. Alcohol Consumption and Risk of Atrial Fibrillation: A Dose-Response Meta-Analysis of Prospective Studies. Frontiers in Cardiovascular Medicine. 2022;9:802163. DOI: 10.3389/fcvm.2022.802163

427. Yang L, Chen H, Shu T, Pan M, Huang W. Risk of incident atrial fibrillation with low-to-moderate alcohol consumption is associated with gender, region, alcohol category: a systematic review and meta-analysis. EP Europace. 2022;24(5):729–46. DOI: 10.1093/europace/euab266

428. Larsson SC, Drca N, Wolk A. Alcohol Consumption and Risk of Atrial Fibrillation. Journal of the American College of Cardiology. 2014;64(3):281–9. DOI: 10.1016/j.jacc.2014.03.048

429. Garg PK, O’Neal WT, Diez‐Roux AV, Alonso A, Soliman EZ, Heckbert S. Negative Affect and Risk of Atrial Fibrillation: MESA. Journal of the American Heart Association. 2019;8(1):e010603. DOI: 10.1161/JAHA.118.010603

430. Wang L, Ding C. Major depression disorder may causally associate with the increased atrial fibrillation risk: evidence from two-sample mendelian randomization analyses. BMC Medical Genomics. 2023;16(1):144. DOI: 10.1186/s12920-023-01565-0

431. Wu H, Li C, Li B, Zheng T, Feng K, Wu Y. Psychological factors and risk of atrial fibrillation: A meta-analysis and systematic review. International Journal of Cardiology. 2022;362:85–92. DOI: 10.1016/j.ijcard.2022.05.048

432. Zhuo C, Ji F, Lin X, Jiang D, Wang L, Tian H et al. Depression and recurrence of atrial fibrillation after catheter ablation: a meta-analysis of cohort studies. Journal of Affective Disorders. 2020;271:27–32. DOI: 10.1016/j.jad.2020.03.118

433. Shi S, Liu T, Liang J, Hu D, Yang B. Depression and Risk of Sudden Cardiac Death and Arrhythmias: A Meta-Analysis. Psychosomatic Medicine. 2017;79(2):153–61. DOI: 10.1097/PSY.0000000000000382

434. Giannone ME, Filippini T, Whelton PK, Chiari A, Vitolo M, Boriani G et al. Atrial Fibrillation and the Risk of Early‐Onset Dementia: A Systematic Review and Meta‐Analysis. Journal of the American Heart Association. 2022;11(14):e025653. DOI: 10.1161/JA-HA.122.025653

435. Koh YH, Lew LZW, Franke KB, Elliott AD, Lau DH, Thiyagarajah A et al. Predictive role of atrial fibrillation in cognitive decline: a systematic review and meta-analysis of 2.8 million individuals. EP Europace. 2022;24(8):1229–39. DOI: 10.1093/europace/euac003

436. Akintade BF, Chapa D, Friedmann E, Thomas SA. The Influence of Depression and Anxiety Symptoms on Health-Related Quality of Life in Patients With Atrial Fibrillation and Atrial Flutter. Journal of Cardiovascular Nursing. 2015;30(1):66–73. DOI: 10.1097/JCN.0000000000000107

437. Bamgbade BA, Sanghai SR, McManus DD, Lessard D, Waring ME, Forrester S et al. Psychosocial and cognitive multimorbidity and health-related quality of life and symptom burden in older adults with atrial fibrillation: The systematic assessment of geriatric elements in atrial fibrillation (SAGE-AF) cohort study. Archives of Gerontology and Geriatrics. 2020;90:104117. DOI: 10.1016/j.archger.2020.104117

438. Taylor EC, O’Neill M, Hughes LD, Moss-Morris R. Atrial fibrillation, quality of life and distress: a cluster analysis of cognitive and behavioural responses. Quality of Life Research. 2022;31(5):1415–25. DOI: 10.1007/s11136-021-03006-w

439. Sadlonova M, Salzmann S, Senges J, Celano CM, Huffman JC, Borggrefe M et al. Generalized anxiety is a predictor of impaired quality of life in patients with atrial fibrillation: Findings from the prospective observational ARENA study. Journal of Psychosomatic Research. 2024;176:111542. DOI: 10.1016/j.jpsychores.2023.111542

440. Gehi AK, Sears S, Goli N, Walker TJ, Chung E, Schwartz J et al. Psychopathology and Symptoms of Atrial Fibrillation: Implications for Therapy. Journal of Cardiovascular Electrophysiology. 2012;23(5):473–8. DOI: 10.1111/j.1540-8167.2011.02264.x

441. Thompson TS, Barksdale DJ, Sears SF, Mounsey JP, Pursell I, Gehi AK. The Effect of Anxiety and Depression on Symptoms Attributed to Atrial Fibrillation. Pacing and Clinical Electrophysiology. 2014;37(4):439–46. DOI: 10.1111/pace.12292

442. Von Eisenhart Rothe A, Hutt F, Baumert J, Breithardt G, Goette A, Kirchhof P et al. Depressed mood amplifies heart-related symptoms in persistent and paroxysmal atrial fibrillation patients: a longitudinal analysis – data from the German Competence Network on Atrial Fibrillation. Europace. 2015;17(9):1354–62. DOI: 10.1093/europace/euv018

443. Kupper N, Van Den Broek KC, Widdershoven J, Denollet J. Subjectively Reported Symptoms in Patients with Persistent Atrial Fibrillation and Emotional Distress. Frontiers in Psychology. 2013;4:192. DOI: 10.3389/fpsyg.2013.00192

444. Rosman L, Lampert R, Ramsey CM, Dziura J, Chui PW, Brandt C et al. Posttraumatic Stress Disorder and Risk for Early Incident Atrial Fibrillation: A Prospective Cohort Study of 1.1 Million Young Adults. Journal of the American Heart Association. 2019;8(19):e013741. DOI: 10.1161/JAHA.119.013741

445. Graff S, Fenger-Grøn M, Christensen B, Pedersen HS, Christensen J, Li J et al. Long-term risk of atrial fibrillation after the death of a partner. Open Heart. 2016;3(1):e000367. DOI: 10.1136/openhrt-2015-000367

446. Suzuki H, Ohira T, Takeishi Y, Hosoya M, Yasumura S, Satoh H et al. Increased prevalence of atrial fibrillation after the Great East Japan Earthquake: Results from the Fukushima Health Management Survey. International Journal of Cardiology. 2015;198:102–5. DOI: 10.1016/j.ijcard.2015.06.151

447. Wei D, Olofsson T, Chen H, Janszky I, Fang F, Ljung R et al. Death of a child and the risk of atrial fibrillation: a nationwide cohort study in Sweden. European Heart Journal. 2021;42(15):1489–95. DOI: 10.1093/eurheartj/ehaa1084

448. Voskoboinik A, Kalman JM, De Silva A, Nicholls T, Costello B, Nanayakkara S et al. Alcohol Abstinence in Drinkers with Atrial Fibrillation. New England Journal of Medicine. 2020;382(1):20–8. DOI: 10.1056/NEJMoa1817591

449. Lee S-R, Choi E-K, Jung J-H, Han K-D, Oh S, Lip GYH. Lower risk of stroke after alcohol abstinence in patients with incident atrial fibrillation: a nationwide population-based cohort study. European Heart Journal. 2021;42(46):4759–68. DOI: 10.1093/eurheartj/ehab315

450. Lee J, Roh S-Y, Yoon W-S, Kim J, Jo E, Bae D-H et al. Changes in alcohol consumption habits and risk of atrial fibrillation: a nationwide population-based study. European Journal of Preventive Cardiology. 2024;31(1):49–58. DOI: 10.1093/eurjpc/zwad270

451. Damanti S, Pasina L, Cortesi L, Rossi PD, Cesari M. Atrial Fibrillation: Possible Influences of Rate and Rhythm Control Strategy on Cognitive Performance. Journal of the American Geriatrics Society. 2018;66(11):2178–82. DOI: 10.1111/jgs.15568

452. Lee S-R, Choi E-K, Lee S-W, Han K-D, Oh S, Lip GYH. Early Rhythm Control and Incident Dementia in Patients With Atrial Fibrillation and Prior Stroke. JACC: Clinical Electrophysiology. 2024;10(7 Pt 1):1409–20. DOI: 10.1016/j.jacep.2024.03.007

453. Lampert R, Burg MM, Jamner LD, Dziura J, Brandt C, Li F et al. Effect of β-blockers on triggering of symptomatic atrial fibrillation by anger or stress. Heart Rhythm. 2019;16(8):1167–73. DOI: 10.1016/j.hrthm.2019.03.004

454. Kim D, Yang P-S, Sung J-H, Jang E, Yu HT, Kim T-H et al. Less dementia after catheter ablation for atrial fibrillation: a nationwide cohort study. European Heart Journal. 2020;41(47):4483–93. DOI: 10.1093/eurheartj/ehaa726

455. Mark DB, Anstrom KJ, Sheng S, Piccini JP, Baloch KN, Monahan KH et al. Effect of Catheter Ablation vs Medical Therapy on Quality of Life Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. JAMA. 2019;321(13):1275–85. DOI: 10.1001/jama.2019.0692

456. Al-Kaisey AM, Parameswaran R, Bryant C, Anderson RD, Hawson J, Chieng D et al. Impact of Catheter Ablation on Cognitive Function in Atrial Fibrillation. JACC: Clinical Electrophysiology. 2023;9(7 Pt 2):1024–34. DOI: 10.1016/j.jacep.2023.02.020

457. Harrison SL, Buckley BJR, Austin P, Lane DA, Lip GYH. Catheter ablation and lower risk of incident dementia and mortality in older adults with atrial fibrillation. Journal of the American Geriatrics Society. 2023;71(11):3357–66. DOI: 10.1111/jgs.18538

458. Zhang S, Zhang N, Liu L, Zheng W, Ma Z-L, Qiao S-Y et al. Global epidemiology of mental disorder in atrial fibrillation between 19982021: A systematic review and meta-analysis. World Journal of Psychiatry. 2024;14(1):179–93. DOI: 10.5498/wjp.v14.i1.179

459. Von Eisenhart Rothe AF, Goette A, Kirchhof P, Breithardt G, Limbourg T, Calvert M et al. Depression in paroxysmal and persistent atrial fibrillation patients: a cross-sectional comparison of patients enroled in two large clinical trials. EP Europace. 2014;16(6):812–9. DOI: 10.1093/europace/eut361

460. Gardarsdottir M, Sigurdsson S, Aspelund T, Rokita H, Launer LJ, Gudnason V et al. Atrial fibrillation is associated with decreased total cerebral blood flow and brain perfusion. EP Europace. 2018;20(8):1252–8. DOI: 10.1093/europace/eux220

461. Singh-Manoux A, Fayosse A, Sabia S, Canonico M, Bobak M, Elbaz A et al. Atrial fibrillation as a risk factor for cognitive decline and dementia. European Heart Journal. 2017;38(34):2612–8. DOI: 10.1093/eurheartj/ehx208

462. Marcus GM, Vittinghoff E, Whitman IR, Joyce S, Yang V, Nah G et al. Acute Consumption of Alcohol and Discrete Atrial Fibrillation Events. Annals of Internal Medicine. 2021;174(11):1503–9. DOI: 10.7326/ M21-0228

463. Gallagher C, Hendriks JML, Elliott AD, Wong CX, Rangnekar G, Middeldorp ME et al. Alcohol and incident atrial fibrillation – A systematic review and meta-analysis. International Journal of Cardiology. 2017;246:46–52. DOI: 10.1016/j.ijcard.2017.05.133

464. Stecker EC, Reinier K, Marijon E, Narayanan K, Teodorescu C, UyEvanado A et al. Public Health Burden of Sudden Cardiac Death in the United States. Circulation: Arrhythmia and Electrophysiology. 2014;7(2):212–7. DOI: 10.1161/CIRCEP.113.001034

465. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical Antipsychotic Drugs and the Risk of Sudden Cardiac Death. New England Journal of Medicine. 2009;360(3):225–35. DOI: 10.1056/NEJ-Moa0806994

466. Murray-Thomas T, Jones ME, Patel D, Brunner E, Shatapathy CC, Motsko S et al. Risk of Mortality (Including Sudden Cardiac Death) and Major Cardiovascular Events in Atypical and Typical Antipsychotic Users: A Study with the General Practice Research Database. Cardiovascular Psychiatry and Neurology. 2013;2013:247486. DOI: 10.1155/2013/247486

467. Amaro-Hosey K, Castells X, Blanco-Silvente L, Loma-Osorio P, Capellà D. Drug-induced Sudden Death: A Scoping Review. Current Drug Safety. 2023;18(3):307–17. DOI: 10.2174/157488631766622 0525115232

468. Wang M, Szepietowska B, Polonsky B, McNitt S, Moss AJ, Zareba W et al. Risk of Cardiac Events Associated With Antidepressant Therapy in Patients With Long QT Syndrome. The American Journal of Cardiology. 2018;121(2):182–7. DOI: 10.1016/j.amjcard.2017.10.010

469. Yokohara S, Hashiguchi M, Shiga T. Psychotherapeutic drug‐induced life‐threatening arrhythmias: A retrospective analysis using the Japanese adverse drug event report database. Journal of Arrhythmia. 2023;39(6):928–36. DOI: 10.1002/joa3.12936

470. Barbui C, Bighelli I, Carrà G, Castellazzi M, Lucii C, Martinotti G et al. Antipsychotic Dose Mediates the Association between Polypharmacy and Corrected QT Interval. PLOS ONE. 2016;11(2):e0148212. DOI: 10.1371/journal.pone.0148212

471. Schwartz PJ, Priori SG, Spazzolini C, Moss AJ, Vincent GM, Napolitano C et al. Genotype-Phenotype Correlation in the Long-QT Syndrome: Gene-Specific Triggers for Life-Threatening Arrhythmias. Circulation. 2001;103(1):89–95. DOI: 10.1161/01.CIR.103.1.89

472. Hintsa T, Määttänen I, Hintsanen M, Swan H, Toivonen L, Kontula K et al. Work Stress and the Long QT Syndrome: High Job Strain and Effort–Reward Imbalance at Work Associated With Arrhythmic Risk in the Long QT Syndrome. Journal of Occupational & Environmental Medicine. 2013;55(12):1387–93. DOI: 10.1097/JOM.0000000000000026

473. Shimizu W, Noda T, Takaki H, Nagaya N, Satomi K, Kurita T et al. Diagnostic value of epinephrine test for genotyping LQT1, LQT2, and LQT3 forms of congenital long QT syndrome. Heart Rhythm. 2004;1(3):276–83. DOI: 10.1016/j.hrthm.2004.04.021

474. Dunbar SB, Dougherty CM, Sears SF, Carroll DL, Goldstein NE, Mark DB et al. Educational and Psychological Interventions to Improve Outcomes for Recipients of Implantable Cardioverter Defibrillators and Their Families: A Scientific Statement From the American Heart Association. Circulation. 2012;126(17):2146–72. DOI: 10.1161/CIR.0b013e31825d59fd

475. Ghezzi ES, Sharman RLS, Selvanayagam JB, Psaltis PJ, Sanders P, Astley JM et al. Burden of mood symptoms and disorders in implantable cardioverter defibrillator patients: a systematic review and meta-analysis of 39 954 patients. Europace. 2023;25(6):euad130. DOI: 10.1093/europace/euad130

476. Miller JL, Thylén I, Elayi SC, Etaee F, Fleming S, Czarapata MM et al. Multi-morbidity burden, psychological distress, and quality of life in implantable cardioverter defibrillator recipients: Results from a nationwide study. Journal of Psychosomatic Research. 2019;120:39–45. DOI: 10.1016/j.jpsychores.2019.03.006

477. Januszkiewicz Ł, Barra S, Providencia R, Conte G, De Asmundis C, Chun JKR et al. Long-term quality of life and acceptance of implantable cardioverter-defibrillator therapy: results of the European Heart Rhythm Association survey. EP Europace. 2022;24(5):860–7. DOI: 10.1093/europace/euac011

478. Ryan K, Benz P, Zosel A, Farkas A, Theobald J. QTc Prolongation in Poison Center Exposures to CredibleMeds List of Substances with “Known Risk of Torsades de Pointes”. Cardiovascular Toxicology. 2022;22(9):866–77. DOI: 10.1007/s12012-022-09764-4

479. Riad FS, Davis AM, Moranville MP, Beshai JF. Drug-Induced QTc Prolongation. The American Journal of Cardiology. 2017;119(2):280–3. DOI: 10.1016/j.amjcard.2016.09.041

480. Niemeijer MN, Van Den Berg ME, Franco OH, Hofman A, Kors JA, Stricker BH et al. Drugs and ventricular repolarization in a general population: the Rotterdam Study. Pharmacoepidemiology and Drug Safety. 2015;24(10):1036–41. DOI: 10.1002/pds.3853

481. Das B, Rawat VS, Ramasubbu SK, Kumar B. Frequency, characteristics and nature of risk factors associated with use of QT interval prolonging medications and related drug-drug interactions in a cohort of psychiatry patients. Therapies. 2019;74(6):599–609. DOI: 10.1016/j. therap.2019.03.008

482. Fayssoil A, Issi J, Guerbaa M, Raynaud J-C, Heroguelle V. Torsade de pointes induced by citalopram and amiodarone. Annales de Cardiologie et d’Angéiologie. 2011;60(3):165–8. DOI: 10.1016/j.ancard.2010.12.002

483. Simpson TF, Salazar JW, Vittinghoff E, Probert J, Iwahashi A, Olgin JE et al. Association of QT-Prolonging Medications With Risk of Autopsy-Defined Causes of Sudden Death. JAMA Internal Medicine. 2020;180(5):698–706. DOI: 10.1001/jamainternmed.2020.0148

484. Polcwiartek C, Kragholm K, Schjerning O, Graff C, Nielsen J. Cardiovascular safety of antipsychotics: a clinical overview. Expert Opinion on Drug Safety. 2016;15(5):679–88. DOI: 10.1517/14740338.2016.1161021

485. NHS Foundation. Guidance on the Use of Antipsychotics. 2022. [Internet] Available at: https://pdf4pro.com/view/guidance-on-the-useof-antipsychotics-77486b.html

486. American Psychiatric Association. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. - Washington, DC: American Psychiatric Association; 2020. - 312p. ISBN 978-0-89042-469-8. Available at: https://psychiatryonline.org/doi/epdf/10.1176/appi.books.9780890424841

487. Bundgaard JS, Thune JJ, Nielsen JC, Videbæk R, Haarbo J, Bruun NE et al. The impact of implantable cardioverter-defibrillator implantation on health-related quality of life in the DANISH trial. EP Europace. 2019;21(6):900–8. DOI: 10.1093/europace/euz018

488. Pan Y, Cai W, Cheng Q, Dong W, An T, Yan J. Association between anxiety and hypertension: a systematic review and meta-analysis of epidemiological studies. Neuropsychiatric Disease and Treatment. 2015;11:1121–30. DOI: 10.2147/NDT.S77710

489. Wu E-L, Chien I-C, Lin C-H. Increased risk of hypertension in patients with anxiety disorders: A population-based study. Journal of Psychosomatic Research. 2014;77(6):522–7. DOI: 10.1016/j.jpsychores.2014.10.006

490. Meng L, Chen D, Yang Y, Zheng Y, Hui R. Depression increases the risk of hypertension incidence: a meta-analysis of prospective cohort studies. Journal of Hypertension. 2012;30(5):842–51. DOI: 10.1097/HJH.0b013e32835080b7

491. Wu E-L, Chien I-C, Lin C-H, Chou Y-J, Chou P. Increased risk of hypertension in patients with major depressive disorder: A population-based study. Journal of Psychosomatic Research. 2012;73(3):169–74. DOI: 10.1016/j.jpsychores.2012.07.002

492. Lim L-F, Solmi M, Cortese S. Association between anxiety and hypertension in adults: A systematic review and meta-analysis. Neuroscience & Biobehavioral Reviews. 2021;131:96–119. DOI: 10.1016/j.neubiorev.2021.08.031

493. Abouzeid M, Kelsall HL, Forbes AB, Sim MR, Creamer MC. Posttraumatic stress disorder and hypertension in Australian veterans of the 1991 Gulf War. Journal of Psychosomatic Research. 2012;72(1):33–8. DOI: 10.1016/j.jpsychores.2011.08.002

494. Sumner JA, Kubzansky LD, Roberts AL, Gilsanz P, Chen Q, Winning A et al. Post-traumatic stress disorder symptoms and risk of hypertension over 22 years in a large cohort of younger and middleaged women. Psychological Medicine. 2016;46(15):3105–16. DOI: 10.1017/S0033291716001914

495. Abell JG, Kivimäki M, Dugravot A, Tabak AG, Fayosse A, Shipley M et al. Association between systolic blood pressure and dementia in the Whitehall II cohort study: role of age, duration, and threshold used to define hypertension. European Heart Journal. 2018;39(33):3119–25. DOI: 10.1093/eurheartj/ehy288

496. Emdin CA, Rothwell PM, Salimi-Khorshidi G, Kiran A, Conrad N, Callender T et al. Blood Pressure and Risk of Vascular Dementia: Evidence From a Primary Care Registry and a Cohort Study of Transient Ischemic Attack and Stroke. Stroke. 2016;47(6):1429–35. DOI: 10.1161/STROKEAHA.116.012658

497. Li C, Zhu Y, Ma Y, Hua R, Zhong B, Xie W. Association of Cumulative Blood Pressure With Cognitive Decline, Dementia, and Mortality. Journal of the American College of Cardiology. 2022;79(14):1321–35. DOI: 10.1016/j.jacc.2022.01.045

498. Cunningham EL, Todd SA, Passmore P, Bullock R, McGuinness B. Pharmacological treatment of hypertension in people without prior cerebrovascular disease for the prevention of cognitive impairment and dementia. Cochrane Database of Systematic Reviews. 2021;5:CD004034. DOI: 10.1002/14651858.CD004034.pub4

499. Hughes D, Judge C, Murphy R, Loughlin E, Costello M, Whiteley W et al. Association of Blood Pressure Lowering With Incident Dementia or Cognitive Impairment: A Systematic Review and Meta-analysis. JAMA. 2020;323(19):1934–44. DOI: 10.1001/jama.2020.4249

500. Peters R, Xu Y, Fitzgerald O, Aung HL, Beckett N, Bulpitt C et al. Blood pressure lowering and prevention of dementia: an individual patient data meta-analysis. European Heart Journal. 2022;43(48):4980–90. DOI: 10.1093/eurheartj/ehac584

501. Forette F. The Prevention of Dementia With Antihypertensive Treatment: New Evidence From the Systolic Hypertension in Europe (SystEur) Study. Archives of Internal Medicine. 2002;162(18):2046–52. DOI: 10.1001/archinte.162.18.2046

502. Wang L, Liu Q, Sun D, Xie J, Lao D, Zhang L. Effects of Combination Treatment in Hypertensive Patients with Depression: A Systematic Review and Meta-Analysis of 27 Randomized Controlled Trials. Therapeutics and Clinical Risk Management. 2022;18:197–211. DOI: 10.2147/TCRM.S347622

503. Graham N, Ward J, Mackay D, Pell JP, Cavanagh J, Padmanabhan S et al. Impact of major depression on cardiovascular outcomes for individuals with hypertension: prospective survival analysis in UK Biobank. BMJ Open. 2019;9(9):e024433. DOI: 10.1136/bmjopen-2018-024433

504. Ogedegbe G, Pickering TG, Clemow L, Chaplin W, Spruill TM, Albanese GM et al. The Misdiagnosis of Hypertension: The Role of Patient Anxiety. Archives of Internal Medicine. 2008;168(22):2459–65. DOI: 10.1001/archinte.168.22.2459

505. Spruill TM, Pickering TG, Schwartz JE, Mostofsky E, Ogedegbe G, Clemow L et al. The impact of perceived hypertension status on anxiety and the white coat effect. Annals of Behavioral Medicine. 2007;34(1):1–9. DOI: 10.1007/BF02879915

506. Jhalani J, Goyal T, Clemow L, Schwartz JE, Pickering TG, Gerin W. Anxiety and outcome expectations predict the white-coat effect: Blood Pressure Monitoring. 2005;10(6):317–9. DOI: 10.1097/00126097-200512000-00006

507. Bhanu C, Nimmons D, Petersen I, Orlu M, Davis D, Hussain H et al. Drug-induced orthostatic hypotension: A systematic review and meta-analysis of randomised controlled trials. PLOS Medicine. 2021;18(11):e1003821. DOI: 10.1371/journal.pmed.1003821

508. Licht CMM, De Geus EJC, Seldenrijk A, Van Hout HPJ, Zitman FG, Van Dyck R et al. Depression Is Associated With Decreased Blood Pressure, but Antidepressant Use Increases the Risk for Hypertension. Hypertension. 2009;53(4):631–8. DOI: 10.1161/HYPERTENSIONAHA.108.126698

509. Breeden M, Brieler J, Salas J, Scherrer JF. Antidepressants and Incident Hypertension in Primary Care Patients. The Journal of the Ameri can Board of Family Medicine. 2018;31(1):22–8. DOI: 10.3122/jabfm.2018.01.170234

510. Wathra R, Mulsant BH, Thomson L, Goldberger KW, Lenze EJ, Karp JF et al. Hypertension and orthostatic hypotension with venlafaxine treatment in depressed older adults. Journal of Psychopharmacology. 2020;34(10):1112–8. DOI: 10.1177/0269881120944154

511. Thase ME. Effects of Venlafaxine on Blood Pressure: A Meta-Analysis of Original Data From 3744 Depressed Patients. The Journal of Clinical Psychiatry. 1998;59(10):502–8. DOI: 10.4088/JCP.v59n1002

512. Johnson EM, Whyte E, Mulsant BH, Pollock BG, Weber E, Begley AE et al. Cardiovascular Changes Associated With Venlafaxine in the Treatment of Late-Life Depression. The American Journal of Geriatric Psychiatry. 2006;14(9):796–802. DOI: 10.1097/01.JGP.0000204328.50105.b3

513. Li Z, Li Y, Chen L, Chen P, Hu Y. Prevalence of Depression in Patients With Hypertension: A Systematic Review and Meta-Analysis. Medicine. 2015;94(31):e1317. DOI: 10.1097/MD.0000000000001317

514. Williamson JD, Pajewski NM, Auchus AP, Bryan RN, Chelune G, Cheung AK et al. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA. 2019;321(6):553–61. DOI: 10.1001/jama.2018.21442

515. Stuhec M, Keuschler J, Serra-Mestres J, Isetta M. Effects of different antihypertensive medication groups on cognitive function in older patients: A systematic review. European Psychiatry. 2017;46:1–15. DOI: 10.1016/j.eurpsy.2017.07.015

516. Den Brok MGHE, Van Dalen JW, Abdulrahman H, Larson EB, Van Middelaar T, Van Gool WA et al. Antihypertensive Medication Classes and the Risk of Dementia: A Systematic Review and Network Meta-Analysis. Journal of the American Medical Directors Association. 2021;22(7):1386-1395.e15. DOI: 10.1016/j.jamda.2020.12.019

517. Chen YJ, Li LJ, Tang WL, Song JY, Qiu R, Li Q et al. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Cochrane Database of Systematic Reviews. 2018;11:CD008170. DOI: 10.1002/14651858.CD008170.pub3

518. Breeden M, Gillis A, Salas J, Scherrer JF. Antidepressant treatment and blood pressure control in patients with comorbid depression and treatment resistant hypertension. Journal of Psychosomatic Research. 2022;153:110692. DOI: 10.1016/j.jpsychores.2021.110692

519. Turvey CL, Schultz K, Arndt S, Wallace RB, Herzog R. Prevalence and Correlates of Depressive Symptoms in a Community Sample of People Suffering from Heart Failure. Journal of the American Geriatrics Society. 2002;50(12):2003–8. DOI: 10.1046/j.1532-5415.2002.50612.x

520. Chobufo MD, Khan S, Agbor VN, Rahman E, Foryoung JB, Jolayemi A et al. 10-Year trend in the prevalence and predictors of depression among patients with heart failure in the USA from 2007–2016. International Journal of Cardiology. 2020;301:123–6. DOI: 10.1016/j.ijcard.2019.09.028

521. Angermann CE, Gelbrich G, Störk S, Schowalter M, Deckert J, Ertl G et al. Somatic correlates of comorbid major depression in patients with systolic heart failure. International Journal of Cardiology. 2011;147(1):66–73. DOI: 10.1016/j.ijcard.2009.07.044

522. Khodneva Y, Goyal P, Levitan EB, Jackson EA, Oparil S, Sterling MR et al. Depressive Symptoms and Incident Hospitalization for Heart Failure: Findings From the REGARDS Study. Journal of the American Heart Association. 2022;11(7):e022818. DOI: 10.1161/JA-HA.121.022818

523. Gustad LT, Laugsand LE, Janszky I, Dalen H, Bjerkeset O. Symptoms of anxiety and depression and risk of heart failure: the HUNT Study. European Journal of Heart Failure. 2014;16(8):861–70. DOI: 10.1002/ejhf.133

524. Garfield LD, Scherrer JF, Hauptman PJ, Freedland KE, Chrusciel T, Balasubramanian S et al. Association of Anxiety Disorders and Depression With Incident Heart Failure. Psychosomatic Medicine. 2014;76(2):128–36. DOI: 10.1097/PSY.0000000000000027

525. Lossnitzer N, Herzog W, Störk S, Wild B, Müller-Tasch T, Lehmkuhl E et al. Incidence rates and predictors of major and minor depression in patients with heart failure. International Journal of Cardiology. 2013;167(2):502–7. DOI: 10.1016/j.ijcard.2012.01.062

526. Machado MO, Veronese N, Sanches M, Stubbs B, Koyanagi A, Thompson T et al. The association of depression and all-cause and cause-specific mortality: an umbrella review of systematic reviews and meta-analyses. BMC Medicine. 2018;16(1):112. DOI: 10.1186/ s12916-018-1101-z

527. Patel N, Chakraborty S, Bandyopadhyay D, Amgai B, Hajra A, Atti V et al. Association between depression and readmission of heart failure: A national representative database study. Progress in Cardiovascular Diseases. 2020;63(5):585–90. DOI: 10.1016/j.pcad.2020.03.014

528. Kewcharoen J, Tachorueangwiwat C, Kanitsoraphan C, Saowapa S, Nitinai N, Vutthikraivit W et al. Association between depression and increased risk of readmission in patients with heart failure: a systematic review and meta-analysis. Minerva Cardiology and Angiology. 2021;69(4):389–97. DOI: 10.23736/S2724-5683.20.05346-3

529. Gathright EC, Goldstein CM, Josephson RA, Hughes JW. Depression increases the risk of mortality in patients with heart failure: A meta-analysis. Journal of Psychosomatic Research. 2017;94:82–9. DOI: 10.1016/j.jpsychores.2017.01.010

530. IsHak WW, Hamilton MA, Korouri S, Diniz MA, Mirocha J, Hedrick R et al. Comparative Effectiveness of Psychotherapy vs Antidepressants for Depression in Heart Failure: A Randomized Clinical Trial. JAMA Network Open. 2024;7(1):e2352094. DOI: 10.1001/jamanetworkopen.2023.52094

531. Angermann CE, Gelbrich G, Störk S, Gunold H, Edelmann F, Wachter R et al. Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression: The MOOD-HF Randomized Clinical Trial. JAMA. 2016;315(24):2683–93. DOI: 10.1001/jama.2016.7635

532. O’Connor CM, Jiang W, Kuchibhatla M, Silva SG, Cuffe MS, Callwood DD et al. Safety and Efficacy of Sertraline for Depression in Patients With Heart Failure. Journal of the American College of Cardiology. 2010;56(9):692–9. DOI: 10.1016/j.jacc.2010.03.068

533. Hedrick R, Korouri S, Tadros E, Darwish T, Cortez V, Triay D et al. The impact of antidepressants on depressive symptom severity, quality of life, morbidity, and mortality in heart failure: a systematic review. Drugs in Context. 2020;9:1–22. DOI: 10.7573/dic.2020-5-4

534. Zambrano J, Celano CM, Januzzi JL, Massey CN, Chung W, Millstein RA et al. Psychiatric and Psychological Interventions for Depression in Patients With Heart Disease: A Scoping Review. Journal of the American Heart Association. 2020;9(22):e018686. DOI: 10.1161/JAHA.120.018686

535. Jeyanantham K, Kotecha D, Thanki D, Dekker R, Lane DA. Effects of cognitive behavioural therapy for depression in heart failure patients: a systematic review and meta-analysis. Heart Failure Reviews. 2017;22(6):731–41. DOI: 10.1007/s10741-017-9640-5

536. Chernoff RA, Messineo G, Kim S, Pizano D, Korouri S, Danovitch I et al. Psychosocial Interventions for Patients With Heart Failure and Their Impact on Depression, Anxiety, Quality of Life, Morbidity, and Mortality: A Systematic Review and Meta-Analysis. Psychosomatic Medicine. 2022;84(5):560–80. DOI: 10.1097/PSY.0000000000001073

537. Tu R-H, Zeng Z-Y, Zhong G-Q, Wu W-F, Lu Y-J, Bo Z-D et al. Effects of exercise training on depression in patients with heart failure: a systematic review and meta-analysis of randomized controlled trials: Effects of exercise training on depression in HF: a systematic review. European Journal of Heart Failure. 2014;16(7):749–57. DOI: 10.1002/ejhf.101

538. Das A, Roy B, Schwarzer G, Silverman MG, Ziegler O, Bandyopadhyay D et al. Comparison of treatment options for depression in heart failure: A network meta-analysis. Journal of Psychiatric Research. 2019;108:7–23. DOI: 10.1016/j.jpsychires.2018.10.007

539. Suzuki T, Shiga T, Kuwahara K, Kobayashi S, Suzuki S, Nishimura K et al. Impact of clustered depression and anxiety on mortality and re-hospitalization in patients with heart failure. Journal of Cardiology. 2014;64(6):456–62. DOI: 10.1016/j.jjcc.2014.02.031

540. Alhurani AS, Dekker RL, Abed MA, Khalil A, Al Zaghal MH, Lee KS et al. The Association of Comorbid Symptoms of Depression and Anxi ety With All-Cause Mortality and Cardiac Rehospitalization in Patients With Heart Failure. Psychosomatics. 2015;56(4):371–80. DOI: 10.1016/j.psym.2014.05.022

541. Zwas DR, Keren A, Amir O, Gotsman I. Treatment of Heart Failure Patients with Anxiolytics Is Associated with Adverse Outcomes, with and without Depression. Journal of Clinical Medicine. 2020;9(12):3967. DOI: 10.3390/jcm9123967

542. Sato Y, Yoshihisa A, Hotsuki Y, Watanabe K, Kimishima Y, Kiko T et al. Associations of Benzodiazepine With Adverse Prognosis in Heart Failure Patients With Insomnia. Journal of the American Heart Association. 2020;9(7):e013982. DOI: 10.1161/JAHA.119.013982

543. Chi Chuang, Fu-Chih Hsiao, Yu-Wen Cheng, Chia-Pin Lin, Ying-Chang Tung, Chia-Tung Wu et al. Benzodiazepines in Patients with Heart Failure and Reduced Ejection Fraction. Acta Cardiologica Sinica. 2022;38(5):573–83. DOI: 10.6515/ACS.202209_38(5).20220406A

544. Ribeirinho-Soares P, Madureira S, Elias C, Gouveia R, Neves A, Amorim M et al. Benzodiazepines use and mortality in chronic heart failure. Polish Archives of Internal Medicine. 2023;133:16464. DOI: 10.20452/pamw.16464

545. He W, Zhou Y, Ma J, Wei B, Fu Y. Effect of antidepressants on death in patients with heart failure: a systematic review and meta-analysis. Heart Failure Reviews. 2020;25(6):919–26. DOI: 10.1007/s10741-019-09850-w

546. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2021;42(36):3599–726. DOI: 10.1093/eurheartj/ehab368